WO2023036137A1 - Process for preparing highly homogenous antibody-drug conjugates for engineered antibodies - Google Patents
Process for preparing highly homogenous antibody-drug conjugates for engineered antibodies Download PDFInfo
- Publication number
- WO2023036137A1 WO2023036137A1 PCT/CN2022/117308 CN2022117308W WO2023036137A1 WO 2023036137 A1 WO2023036137 A1 WO 2023036137A1 CN 2022117308 W CN2022117308 W CN 2022117308W WO 2023036137 A1 WO2023036137 A1 WO 2023036137A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- drug
- antigen
- process according
- binding moiety
- Prior art date
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 206
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 198
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 109
- 230000008569 process Effects 0.000 claims abstract description 75
- 239000003814 drug Substances 0.000 claims description 147
- 229940079593 drug Drugs 0.000 claims description 140
- 239000000427 antigen Substances 0.000 claims description 129
- 108091007433 antigens Proteins 0.000 claims description 129
- 102000036639 antigens Human genes 0.000 claims description 129
- 230000027455 binding Effects 0.000 claims description 92
- 108091008874 T cell receptors Proteins 0.000 claims description 72
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 72
- 206010028980 Neoplasm Diseases 0.000 claims description 55
- 229910021645 metal ion Inorganic materials 0.000 claims description 47
- 239000003638 chemical reducing agent Substances 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 230000002829 reductive effect Effects 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 22
- 229960000575 trastuzumab Drugs 0.000 claims description 22
- 239000000872 buffer Substances 0.000 claims description 20
- 229910001428 transition metal ion Inorganic materials 0.000 claims description 20
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 19
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 229960002087 pertuzumab Drugs 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000007800 oxidant agent Substances 0.000 claims description 12
- 229950001460 sacituzumab Drugs 0.000 claims description 12
- 208000035473 Communicable disease Diseases 0.000 claims description 11
- 239000007853 buffer solution Substances 0.000 claims description 11
- 230000001590 oxidative effect Effects 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 8
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 5
- KRHAHEQEKNJCSD-UHFFFAOYSA-N Dihydroasparagusic acid Natural products OC(=O)C(CS)CS KRHAHEQEKNJCSD-UHFFFAOYSA-N 0.000 claims description 5
- 229960005395 cetuximab Drugs 0.000 claims description 5
- JYGAZEJXUVDYHI-UHFFFAOYSA-N dihydroartemisininic acid Natural products C1CC(C)=CC2C(C(C)C(O)=O)CCC(C)C21 JYGAZEJXUVDYHI-UHFFFAOYSA-N 0.000 claims description 5
- 229930188854 dolastatin Natural products 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- 229960000446 abciximab Drugs 0.000 claims description 3
- 229960002964 adalimumab Drugs 0.000 claims description 3
- 229960002459 alefacept Drugs 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- 229960004669 basiliximab Drugs 0.000 claims description 3
- 229960003270 belimumab Drugs 0.000 claims description 3
- 229950008086 bezlotoxumab Drugs 0.000 claims description 3
- 150000001649 bromium compounds Chemical group 0.000 claims description 3
- 229930195731 calicheamicin Natural products 0.000 claims description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 3
- 229960001838 canakinumab Drugs 0.000 claims description 3
- 229960003115 certolizumab pegol Drugs 0.000 claims description 3
- 229960002806 daclizumab Drugs 0.000 claims description 3
- 229960001251 denosumab Drugs 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 229960000284 efalizumab Drugs 0.000 claims description 3
- 229960001743 golimumab Drugs 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 229940037993 inflectra Drugs 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- 229960005435 ixekizumab Drugs 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 229960005027 natalizumab Drugs 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229950008516 olaratumab Drugs 0.000 claims description 3
- 229960000470 omalizumab Drugs 0.000 claims description 3
- 229960000402 palivizumab Drugs 0.000 claims description 3
- 229960001972 panitumumab Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 229960004641 rituximab Drugs 0.000 claims description 3
- 229960004540 secukinumab Drugs 0.000 claims description 3
- 229960003989 tocilizumab Drugs 0.000 claims description 3
- 229960003824 ustekinumab Drugs 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 2
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 claims description 2
- 229930013292 trichothecene Natural products 0.000 claims description 2
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 230000021615 conjugation Effects 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 42
- -1 transition metal salts Chemical class 0.000 description 37
- 239000000203 mixture Substances 0.000 description 32
- 238000006722 reduction reaction Methods 0.000 description 27
- 239000000243 solution Substances 0.000 description 26
- 125000005647 linker group Chemical group 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 21
- 230000009467 reduction Effects 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 15
- 101100494448 Caenorhabditis elegans cab-1 gene Proteins 0.000 description 14
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 239000000562 conjugate Substances 0.000 description 12
- 238000010168 coupling process Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 238000011068 loading method Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- ORFNVPGICPYLJV-YTVPMEHESA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C=CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 ORFNVPGICPYLJV-YTVPMEHESA-N 0.000 description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229910052723 transition metal Inorganic materials 0.000 description 7
- 239000011701 zinc Substances 0.000 description 7
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 6
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 108010093470 monomethyl auristatin E Proteins 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000011592 zinc chloride Substances 0.000 description 6
- 235000005074 zinc chloride Nutrition 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- 101100330723 Arabidopsis thaliana DAR2 gene Proteins 0.000 description 5
- 101100330727 Arabidopsis thaliana DAR6 gene Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000008176 lyophilized powder Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 4
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- NLMBVBUNULOTNS-HOKPPMCLSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-o Chemical compound C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN3C(C=CC3=O)=O)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 NLMBVBUNULOTNS-HOKPPMCLSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 108010059074 monomethylauristatin F Proteins 0.000 description 4
- 210000004882 non-tumor cell Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000001047 pyretic effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000012536 storage buffer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 150000003751 zinc Chemical class 0.000 description 3
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 3
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 2
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 2
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101100396742 Homo sapiens IL3RA gene Proteins 0.000 description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 108010044540 auristatin Proteins 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- KPWJBEFBFLRCLH-UHFFFAOYSA-L cadmium bromide Chemical compound Br[Cd]Br KPWJBEFBFLRCLH-UHFFFAOYSA-L 0.000 description 2
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 2
- OKIIEJOIXGHUKX-UHFFFAOYSA-L cadmium iodide Chemical compound [Cd+2].[I-].[I-] OKIIEJOIXGHUKX-UHFFFAOYSA-L 0.000 description 2
- 229910001493 cadmium tetrafluoroborate Inorganic materials 0.000 description 2
- BAAYWLNVHTVAJJ-UHFFFAOYSA-L cadmium(2+);diformate Chemical compound [Cd+2].[O-]C=O.[O-]C=O BAAYWLNVHTVAJJ-UHFFFAOYSA-L 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 230000006334 disulfide bridging Effects 0.000 description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- ZHWDIQJDQPXVJF-UHFFFAOYSA-L mercury(2+);diformate Chemical compound [Hg+2].[O-]C=O.[O-]C=O ZHWDIQJDQPXVJF-UHFFFAOYSA-L 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000009938 salting Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- SRWMQSFFRFWREA-UHFFFAOYSA-M zinc formate Chemical compound [Zn+2].[O-]C=O SRWMQSFFRFWREA-UHFFFAOYSA-M 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- CDXHOBQTVYVWHA-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonimidic acid Chemical compound S1C(C)=NN=C1N=S(O)(=O)C1=CC=C(N)C=C1 CDXHOBQTVYVWHA-UHFFFAOYSA-N 0.000 description 1
- ALEVUYMOJKJJSA-UHFFFAOYSA-N 4-hydroxy-2-propylbenzoic acid Chemical class CCCC1=CC(O)=CC=C1C(O)=O ALEVUYMOJKJJSA-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 241000224424 Acanthamoeba sp. Species 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010001324 Adrenal atrophy Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101100330725 Arabidopsis thaliana DAR4 gene Proteins 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 102100020998 Aspartate beta-hydroxylase domain-containing protein 1 Human genes 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 241000223848 Babesia microti Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241001235572 Balantioides coli Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 108010085074 Brevican Proteins 0.000 description 1
- 102100032312 Brevican core protein Human genes 0.000 description 1
- 241000244038 Brugia malayi Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 1
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102100024220 CD180 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010058905 CD44v6 antigen Proteins 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100035350 CUB domain-containing protein 1 Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- 208000020119 Caplan syndrome Diseases 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010619 Congenital rubella infection Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 241000295636 Cryptosporidium sp. Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010011715 Cyclitis Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 102100030438 Derlin-1 Human genes 0.000 description 1
- 101710178882 Derlin-1 Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 102100020743 Dipeptidase 1 Human genes 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 208000005235 Echovirus Infections Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 description 1
- 101710120224 Fc receptor-like protein 1 Proteins 0.000 description 1
- 102100031511 Fc receptor-like protein 2 Human genes 0.000 description 1
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 1
- 208000028387 Felty syndrome Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101710181403 Frizzled Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000783987 Homo sapiens Aspartate beta-hydroxylase domain-containing protein 1 Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 1
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 description 1
- 101000980829 Homo sapiens CD180 antigen Proteins 0.000 description 1
- 101000737742 Homo sapiens CUB domain-containing protein 1 Proteins 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 101100499854 Homo sapiens DPEP1 gene Proteins 0.000 description 1
- 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 description 1
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 description 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001091205 Homo sapiens KiSS-1 receptor Proteins 0.000 description 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000829779 Homo sapiens Probable G-protein coupled receptor 19 Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101000825475 Homo sapiens Protein shisa-2 homolog Proteins 0.000 description 1
- 101000853730 Homo sapiens RING finger and transmembrane domain-containing protein 2 Proteins 0.000 description 1
- 101000936922 Homo sapiens Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Proteins 0.000 description 1
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 description 1
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 description 1
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 1
- 101000834937 Homo sapiens Tomoregulin-1 Proteins 0.000 description 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 102100034845 KiSS-1 receptor Human genes 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001245510 Lambia <signal fly> Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000235388 Mucorales Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- RTGDFNSFWBGLEC-UHFFFAOYSA-N Mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1CC=C(C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-UHFFFAOYSA-N 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
- 241000224438 Naegleria fowleri Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241001126259 Nippostrongylus brasiliensis Species 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 102100037603 P2X purinoceptor 5 Human genes 0.000 description 1
- 101710189969 P2X purinoceptor 5 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 102100023417 Probable G-protein coupled receptor 19 Human genes 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102100022938 Protein shisa-2 homolog Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 102100035928 RING finger and transmembrane domain-containing protein 2 Human genes 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100027732 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Human genes 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 description 1
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 241000244158 Taenia crassiceps Species 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100026159 Tomoregulin-1 Human genes 0.000 description 1
- 102100026160 Tomoregulin-2 Human genes 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000037831 acute erythroleukemic leukemia Diseases 0.000 description 1
- 208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 description 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 201000007538 anal carcinoma Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 208000007456 balantidiasis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000015440 bird fancier lung Diseases 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- QCUOBSQYDGUHHT-UHFFFAOYSA-L cadmium sulfate Chemical compound [Cd+2].[O-]S([O-])(=O)=O QCUOBSQYDGUHHT-UHFFFAOYSA-L 0.000 description 1
- 229910000369 cadmium(II) sulfate Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002615 dalfopristin Drugs 0.000 description 1
- SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 description 1
- 108700028430 dalfopristin Proteins 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 125000000481 dehydro ascorbic acid group Chemical group 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical class CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005298 gastrointestinal allergy Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 239000007946 hypodermic tablet Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- NGYIMTKLQULBOO-UHFFFAOYSA-L mercury dibromide Chemical compound Br[Hg]Br NGYIMTKLQULBOO-UHFFFAOYSA-L 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 229910000372 mercury(II) sulfate Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- DASWEROEPLKSEI-UIJRFTGLSA-N monomethyl auristatin e Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 1
- MFRNYXJJRJQHNW-NARUGQRUSA-N monomethyl auristatin f Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)C([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-NARUGQRUSA-N 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 229940124633 peptidic drug Drugs 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 229960005442 quinupristin Drugs 0.000 description 1
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 description 1
- 108700028429 quinupristin Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present disclosure relates to a process for preparing antibody-drug conjugates (ADCs) .
- ADCs antibody-drug conjugates
- the present disclosure relates to a bio-conjugation process for preparing highly homogenous antibody-drug conjugates (ADCs) for engineered antibodies, specifically, antibodies that are engineered to comprise TCR constant regions in one Fab arm.
- antibodies conjugated to labels and reporter groups such as fluorophores, radioisotopes and enzymes find use in labelling and imaging applications, while conjugation to cytotoxic agents and chemotherapy drugs allows targeted delivery of such agents to specific tissues or structures, for example particular cell types or growth factors, minimizing the impact on normal, healthy tissue and significantly reducing the side effects associated with chemotherapy treatments.
- Bispecific antibody refers to a type of antibodies designed to recognize two different epitopes or antigens and aims to treat multifaceted, complex diseases by engaging two disease targets with one molecule. It comes in many formats.
- WO2019057122 and WO2020057610 disclose examples of WuXiBody TM platform that enables almost any monoclonal antibody (mAb) sequence pair to be assembled into a bispecific construct and its unique structural flexibility makes the platform convenient to build various formats with different valency.
- the bispecific antibody generated by the platform also is stable and has no aggregation issue during production.
- ADC Antibody-drug conjugates
- ADC is conjugate of an antibody and a drug and have extensive potential therapeutic applications in several disease areas, particularly in cancer, and become a novel targeted drug for disease treatment.
- ADC contains an antibody for targeting, a connector or linker for drug attachment and a high potent payload (e.g., a drug) as effector.
- the antibody by its specificity, directs the drug to its target to release. Since the approvals of Adcetris in 2011 and Kadcyla in 2013 by US FDA, ADC drug development has widely spread for the treatment of cancer. Recently, it has been demonstrated that ADC based on bispecific antibody (e.g. ZW49) can be more efficacious in cancer treatment.
- bispecific antibody e.g. ZW49
- ADC One of the problems facing the conventional conjugation of ADC is the heterogeneity of the ADC molecules where the drug moieties are attached at several sites on the antibody, for example, ranging from 0 to 8 per antibody (Drug-Antibody Ratio, DAR) by cysteine chemistry.
- DAR Drug-Antibody Ratio
- ADC molecules of such a mixture not only bring difficulties in analysis and characterization, but also potentially have different pharmacokinetic, distribution, toxicity and efficacy profiles. And non-specific conjugation also frequently results in impaired antibody function.
- the present disclosure has an object to develop a novel conjugation process which can generate ADCs with improved homogeneity for a certain type of bispecific antibody, and has simple manipulation and reduced cost.
- the resultant ADCs have a high content of D2, D6 or D2+4 ADCs, depending on the specific process applied.
- the ADCs generated by the conjugation process of the disclosure further have optimized safety and efficacy.
- the present disclosure relates to a combination of metal ion chelating technology and a certain type of bispecific antibody, the WuXiBody, for developing new conjugation processes.
- the homogeneity of antibody-drug conjugate (ADC) products generated from the conjugation process of the present disclosure can be dramatically improved.
- ADC products site-specifically conjugated with two different drug moieties can be obtained.
- the disclosure provides a process for preparing an antibody-drug conjugate (ADC) , wherein the antibody comprises a pair of T cell receptor (TCR) constant regions instead of CH1 and CL domains in at least one arm, and the pair of TCR constant regions is capable of forming a non-native interchain disulfide bond (s) , and wherein the process comprises the following steps:
- step (b) introducing an excess amount of a linker-drug moiety to react with reduced thiol groups resulted from step (a) ;
- the process further comprises adding an effective amount of oxidant to re-oxidize the unreacted thiol groups after step (b) and before recovering the resultant antibody-drug conjugate.
- the inventors have surprisingly found that due to steric hindrance, the non-native interchain disulfide bond (s) between the pair of TCR constant regions is/are not accessible to reductants and thus cannot be reduced for drug conjugation.
- the antibody as described herein comprises a first and a second antigen-binding moiety, wherein the first antigen-binding moiety comprises: a first heavy chain variable domain (VH) operably linked to a T cell receptor (TCR) constant region (C1) , and a first light chain variable domain (VL) operably linked to a second TCR constant region (C2) , wherein C1 and C2 are capable of forming a non-native interchain disulfide bond, and
- the second antigen-binding moiety is in Fab, scFv or VHH format.
- the second antigen-binding moiety is in Fab format and comprises: a second VH operably linked to an antibody heavy chain CH1 domain, and a second VL operably linked to an antibody light chain constant (CL) domain.
- the second antigen-binding moiety is in scFv format and comprises: a second VH operably linked to a second VL.
- the second antigen-binding moiety is in VHH format and comprises a single variable domain.
- the antibody is a bispecific antibody with the first and second antigen-binding moieties targeting different antigens or epitopes. In some other embodiments, the antibody is a mono-specific antibody with the first and second antigen-binding moieties targeting the same epitope.
- the C1 region and C2 regions of the antibody as disclosed herein comprises an engineered T cell receptor (TCR) constant regions.
- TCR T cell receptor
- the C1 region may comprise the amino acid sequence of SEQ ID No: 2, 7 or a variant thereof with at least 90%identity; and the C2 region may comprise the amino acid sequence of SEQ ID No: 4, 8, 9 or a variant thereof with at least 90%identity.
- the C1 and C2 regions are capable of forming a dimer, and the non-native interchain disulfide bond (s) is/are capable of stabilizing the dimer.
- amino acid C58 in SEQ ID No: 2 and amino acid C49 in SEQ ID No: 4 are capable of forming a non-native interchain disulfide bond.
- the antibody comprises an IgG Fc region, such as an IgG1, IgG2, IgG3 or IgG4 isotype.
- the Fc region further comprises a knob into hole structure.
- the sequence of the hinge region and the Fc region in one chain is as shown in SEQ ID No: 5
- the sequence of the hinge region and the Fc region in the other chain is as shown in SEQ ID No: 6.
- the antibody comprises the following structure (E17) : in the 1 st heavy chain, VH1-C1-hinge-Fc; in the 2 nd heavy chain, VH2-CH1-hinge-Fc; in the 1 st light chain, VL1-C2; and in the 2 nd light chain, VL2-CL, wherein VH1 and VL1 refer to the first VH and VL and VH2 and VL2 refer to the second VH and VL, respectively.
- “-” represents an operable linkage, generally via a peptide linker.
- the antibody comprises the following structure: in the 1 st heavy chain, VH1-C1-hinge-Fc-scFv; in the 2 nd heavy chain, VH1- CH1-hinge-Fc-scFv; in the 1 st light chain, VL1-C2; and in the 2 nd light chain, VL1-CL.
- the scFv constitutes the second antigen-binding moiety and can also be replaced by a VHH format.
- the incubation in step (a) is performed in the presence of an effective amount of a metal ion (s) such as a divalent metal ion (s) and a transition metal ion (s) .
- a metal ion such as a divalent metal ion (s) and a transition metal ion (s) .
- the resultant antibody-drug conjugate comprises D2 in a content higher than 80 wt%, for example, higher than 85 wt%, higher than 90 wt%, or higher than 95 wt %, on the basis of total weight of D0 and D2.
- the incubation in step (a) is performed in the presence of an effective amount of metal ions such as a divalent metal ion or a transition metal ion and the process further comprises between steps (b) and (c) : removing the transition metal ions or divalent metal ions from the product of step (b) , then introducing a reductant again and incubating with an excess amount of a different linker-drug moiety.
- the resultant antibody-drug conjugate comprises D2+4 in a content higher than 65 wt%, for example, higher than 70 wt%, higher than 80 wt%, or higher than 90 wt%, on the basis of total weight of ADCs.
- the incubation in step (a) is not performed in the presence of an effective amount of transition metal ions or divalent metal ions.
- the resultant antibody-drug conjugate comprises D6 in a content higher than 85 wt%, for example, higher than 90 wt%, higher than 91 wt%, higher than 92 wt%, or higher than 93 wt%, on the basis of total weight of D0, D2, D4, and D6.
- the present disclosure provides a process for preparing an antibody-drug conjugate (ADC) , wherein the antibody comprises a first and second antigen-binding moiety,
- the first antigen-binding moiety comprises: a first heavy chain variable domain (VH) operably linked to a T cell receptor (TCR) constant region (C1) , and a first light chain variable domain (VL) operably linked to a second TCR constant region (C2) , and
- the second antigen-binding moiety comprises: a second VH operably linked to an antibody heavy chain CH1 domain, and a second VL operably linked to an antibody light chain constant (CL) domain,
- step (b) introducing an excess amount of a first linker-drug moiety to react with reduced thiol groups resulted from step (a) ;
- step (c) removing the transition metal ions or divalent metal ions from the product of step (b) ;
- the process further comprises adding an effective amount of oxidant to re-oxidize the unreacted thiol groups after step (d) .
- the reductants added in step (a) and (d) are different, such as one is TCEP and the other is TDD. In some other embodiments, the reductants added in step (a) and (d) are the same, e.g. both are TCEP.
- the resultant antibody-drug conjugate comprises D2+4 in a content higher than 65 wt%, for example, higher than 70 wt%, higher than 80 wt%, or higher than 90 wt%, on the basis of total weight of ADCs.
- the first drug is MMAF and the second drug is DXD.
- the metal ions in step (a) are selected from a group of divalent ions and transition metal ions comprising Zn2+, Cd2+, Hg2+, Ca2+, Mg2+, or any combination thereof.
- the metal ion in step (a) is Zn2+.
- the transition metal ion which is suitable to be used in the conjugation processes of the present disclosure may include, but not limited to, Zn 2+ , Cd 2+ , Hg 2+ , and the like. Among others, Zn 2+ , Ca 2+ and Mg 2+ may be used due to their easily availability and low cost.
- suitable transition metal salts or divalent metal ions may be added in step (a) as long as they are soluble in the reaction solution so that free transition metal ions can be released in the reaction solution.
- ZnCl 2 , Zn (NO 3 ) 2 , ZnSO 4 , Zn (CH 3 COO) 2 , ZnI 2 , ZnBr 2 , Zinc Formate, and zinc tetrafluoroborate may be mentioned as suitable zinc salts.
- CaCl 2 , Ca (NO 3 ) 2 , CaSO 4 , MgCl 2 , Mg (NO 3 ) 2 , and MgSO 4 can be applied.
- transition metal salts which are soluble and can release free Cd 2+ , or Hg 2+ ions in the reaction solution
- the buffer system used in step (a) is selected from a group comprising Hepes, Histidine buffer, PBS, and MES, and the pH value is about 5.5 to 8.
- the antibody to be conjugated is added in step (a) to be a final concentration of about 0.01 to 0.1 mM.
- step (a) is performed at a temperature of about -10°C to 37°C, for example, at about 0°C to 20°C.
- the reductant in step (a) is TCEP.
- the oxidant is DHAA.
- the linker-drug moiety is maleimide bearing a drug, an organic bromide bearing a drug, or an organic iodide bearing a drug.
- variable regions of the first and second antigen binding moiety are derived from antibodies which are already known, on the market, or developed de novo, such as any of the following antibodies: trastuzumab, pertuzumab, sacituzumab, abciximab, adalimumab, alefacept, alemtuzumab, basiliximab, belimumab, bezlotoxumab, canakinumab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, golimumab, inflectra, ipilimumab, ixekizumab, natalizumab, nivolumab, olaratumab, omalizumab, palivizumab, panitumumab, pembrolizumab, rituximab, tocilizumab, trastuzumab, trastuzum
- the first VH and the first VL are from Trastuzumab and the second VH and the second VL are from pertuzumab, or vice versa. In some other embodiments, the first VH and the first VL are from Trastuzumab and the second VH and the second VL are from sacituzumab, or vice versa.
- the drug to be conjugated is selected from a group comprising diagnostic agents, therapeutic agents and labelling agents.
- the metal ions will be removed in purification step by using EDTA as chelating reagent, which will be filtered out in subsequent dialysis, ultrafiltration or gel filtration.
- the present disclosure provides the antibody-drug conjugates prepared by the process of any one of disclosed processes.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of the antibody-drug conjugate as disclosed herein and a pharmaceutically acceptable carrier or vehicle.
- the present disclosure provides use of the antibody-drug conjugates as disclosed herein in the manufacture of a pharmaceutical composition or a kit for treating a condition or disorder in a subject.
- the present disclosure provides a method for treating a condition or disorder in a subject, comprising a step of administrating to the subject a therapeutically effective amount of the antibody-drug conjugate or the pharmaceutical composition as disclosed herein.
- the condition or disorder is a tumor, cancer, autoimmune disease, or infectious disease.
- the cancer is breast cancer.
- the subject may be a mammal, for example, a human.
- FIG. 1A Reaction scheme according to some embodiments wherein three pairs of interchain disulfide bonds of the bispecific antibody cAb1 (Trastuzumab x Pertuzumab) are reduced and site-specifically conjugated with MC-MMAF (Fig. 1A) ; HIC profile of cAb1 conjugation which shows DAR6 abundance (Fig. 1B) ; and Mass Spectrometry profile of cAb1 conjugation (Fig. 1C) .
- Figure 1D is the HIC profile of two other bispecific antibodies cAb3 and cAb4 which are similarly conjugated.
- FIG. 2A Reaction scheme according to some embodiments wherein Zn 2+ is added and only one pair of interchain disulfide bonds of the bispecific antibody is reduced and site-specifically conjugated with MC-MMAF (Fig. 2A) ; HIC profile of four bispecific antibodies cAb1, cAb2, cAb3 and cAb4 (Fig. 2B) conjugated as described in (Fig. 2A) .
- FIG. 3A Reaction scheme according to some embodiments wherein the bispecific antibody cAb1 is conjugated in two steps with two different drugs (e.g. MMAF and DXD) , respectively (Fig. 3A) ; MS profiles of resultant cAb1 ADC (Fig. 3B) , cAb2 ADC (Fig. 3C) , cAb3 ADC (Fig. 3D) and cAb4 ADC (Fig. 3E) .
- two different drugs e.g. MMAF and DXD
- the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 30, 25, 20, 25, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1%to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- the terms “about” or “approximately” when preceding a numerical value indicates the value plus or minus a range of 15%, 10%, 5%, or 1%.
- Antibody-drug conjugate refers to a conjugate formed by covalently coupling a drug to an antibody directly or indirectly via one or more suitable linkers.
- ADC is generally in a format of antibody-linker-drug conjugate.
- the Antibody-drug conjugates combine ideal properties of both antibodies and cytotoxic drugs (or those of other properties) by targeting potent cytotoxic (or other) drugs to the antigen-expressing tumor cells (or other cells/organs) , thereby enhancing their anti-tumor (or other medicinal) activity.
- ADCs are designed with the intention to discriminate between healthy cells and diseased tissue such as tumor cells in a tumor.
- drug refers to any cytotoxic molecule which has for example, an antitumor effect, anti-infection or anti-inflammation effect, and has at least one substituted group or a partial structure allowing connection to a linker structure.
- the drug may kill cells (e.g. cancer cells) and/or inhibit growth, proliferation, or metastasis of cells (e.g. cancer cells) , thereby reducing, alleviating, or eliminating one or more symptoms of a disease or disorder (e.g. cancer) .
- linker refers to a reactive molecule which contains at least two reactive groups, one of which can covalently bond a drug molecule and the other of which can covalently couple to an antibody.
- antibody encompasses any immunoglobulin, monoclonal antibody, polyclonal antibody, multi-specific antibody, bispecific antibody, multivalent or bivalent antibody that binds to a specific antigen.
- a native intact antibody comprises two heavy chains and two light chains. Each heavy chain consists of a variable region ( “HCVR” ) and a first, second, and third constant region (CH1, CH2 and CH3) , while each light chain consists of a variable region (“LCVR” ) and a constant region (CL) .
- HCVR variable region
- CH1, CH2 and CH3 first, second, and third constant region
- LCVR variable region
- Mammalian heavy chains are classified as ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , and mammalian light chains are classified as ⁇ or ⁇ .
- the antibody generally has a “Y” shape, with the stem of the Y consisting of the second and third constant regions of two heavy chains bound together via disulfide bonding.
- Each arm of the Y includes the variable region and first constant region of a single heavy chain bound to the variable and constant regions of a single light chain.
- the variable regions of the light and heavy chains are responsible for antigen binding.
- the variable regions in both chains generally contain three highly variable loops called the complementarity determining regions (CDRs) (light (L) chain CDRs including LCDR1, LCDR2, and LCDR3, heavy (H) chain CDRs including HCDR1, HCDR2, HCDR3) .
- CDRs complementarity determining regions
- CDR boundaries for antibodies may be defined or identified by the conventions of Kabat, Chothia, or Al-Lazikani (Al-Lazikani, B., Chothia, C., Lesk, A.M., J. Mol. Biol., 273 (4) , 927 (1997) ; Chothia, C. et al., J Mol Biol. Dec 5; 186 (3) : 651-63 (1985) ; Chothia, C. and Lesk, A.M., J. Mol. Biol., 196, 901 (1987) ; Chothia, C. et al., Nature. Dec 21-28; 342 (6252) : 877-83 (1989) ; Kabat E.A.
- Each HCVR and LCVR comprises four FRs, and the CDRs and FRs are arranged from amino terminus to carboxy terminus in the order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- the constant regions of the heavy and light chains are not involved in antigen binding, but exhibit various effector functions. Antibodies are assigned to classes based on the amino acid sequence of the constant region of their heavy chain.
- the five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, which are characterized by the presence of ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ heavy chains, respectively.
- IgG1 ( ⁇ 1 heavy chain) IgG2 ( ⁇ 2 heavy chain)
- IgG3 ( ⁇ 3 heavy chain) IgG4 ( ⁇ 4 heavy chain)
- IgA1 ( ⁇ 1 heavy chain) ⁇ 2 heavy chain
- IgA2 ( ⁇ 2 heavy chain) Several of the major antibody classes are divided into subclasses such as IgG1 ( ⁇ 1 heavy chain) , IgG2 ( ⁇ 2 heavy chain) , IgG3 ( ⁇ 3 heavy chain) , IgG4 ( ⁇ 4 heavy chain) , IgA1 ( ⁇ 1 heavy chain) , or IgA2 ( ⁇ 2 heavy chain) .
- antibody fragment comprise a portion of a full-length antibody, generally the antigen binding or variable region thereof.
- antibody fragments include Fab, Fab’, F (ab’) 2, and Fv fragments; diabodies; linear antibodies; minibodies (Olafsen et al. (2004) Protein Eng. Design &Sel. 17 (4) : 315-323) , fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDR (complementary determining region) , and epitope -binding fragments of any described herein which immunospecifically bind to cancer cell antigens, viral antigens or microbial antigens, single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
- antigen-binding moiety refers to an antibody fragment formed from a portion of an antibody comprising one or more CDRs, or any other antibody fragment that binds to an antigen but does not comprise an intact native antibody structure.
- antigen-binding moiety include, without limitation, a variable domain, a variable region, a diabody, a Fab, a Fab’, a F (ab’) 2, an Fv fragment, a scFv, a disulfide stabilized Fv fragment (dsFv) , a (dsFv) 2, a bispecific dsFv (dsFv-dsFv’) , a disulfide stabilized diabody (ds diabody) , a multispecific antibody, a camelized single domain antibody, a nanobody, a domain antibody, and a bivalent domain antibody.
- an antigen-binding moiety is capable of binding to the same antigen to which the parent antibody binds.
- an antigen-binding moiety may comprise one or more CDRs from a particular human antibody grafted to a framework region from one or more different human antibodies.
- Fab with regard to an antibody refers to that portion of the antibody consisting of a single light chain (both variable and constant regions) associating to the variable region and first constant region of a single heavy chain by a disulfide bond.
- both the first and second antigen-binding moieties of the antibody to be conjugated are in Fab format.
- the constant regions (i.e. CH1 and CL) of both chains of the Fab are replaced with engineered or modified TCR constant regions.
- Fc with regard to an antibody refers to that portion of the antibody comprising the second (CH2) and third (CH3) constant regions of a first heavy chain bound to the second and third constant regions of a second heavy chain via disulfide bonding, and optionally a hinge region.
- the Fc portion of the antibody is responsible for various effector functions such as ADCC, and CDC, but does not function in antigen binding.
- “Hinge region” in terms of an antibody includes the portion of a heavy chain molecule that joins the CH1 domain to the CH2 domain. This hinge region comprises approximately 25 amino acid residues and is flexible, thus allowing the two N-terminus antigen binding regions to move independently.
- knob into hole refers to engineering the CH3 domain of antibody Fc region to create either a “knob” or a “hole” in each heavy chain to promote heterodimerization.
- a “knob” is created by replacing T366 with a bulky residue W on one heavy chain, and the corresponding “hole” is made by triple mutations of T366S, L368A and Y407V on the other heavy chain.
- the knob-into-hole structure may comprise other substitutions, as familiar in the art.
- the “EU numbering system” or “EU index” is generally used when referring to a residue in an immunoglobulin heavy chain constant region (e.g., the EU index reported in Kabat et al.
- sequences of Proteins of Immunological Interest 5th Ed. ) , US Dept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242) .
- references to residue numbers in the constant domain of Fc regions means residue numbering by the EU numbering system.
- sequence of the hinge region and the Fc region in one chain is as shown in SEQ ID No: 5
- sequence of the hinge region and the Fc region in the other chain is as shown in SEQ ID No: 6.
- the term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes) , each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies.
- the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al. (1975) Nature 256: 495, or may be made by recombinant DNA methods (see for example: US 4816567; US 5807715) .
- the monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in e.g. Clackson et al. (1991) Nature, 352: 624-628; Marks et al. (1991) J. Mol. Biol., 222: 581-597.
- a “WuXiBody” as used herein refers to a bispecific antibody comprising a soluble chimeric protein with the variable domains of an antibody and the constant domains of a TCR (e.g. in the first antigen-binding moiety) , wherein the subunits (such as alpha and beta domains) of the TCR constant domains are linked by one or more engineered disulfide bonds.
- the WuXiBody also encompasses WuXiBody 2.0 antibodies which comprise a numerous variety of modified TCR constant domain sequences (see WO2022/156687) .
- the TCR constant domains may be engineered to form more than one pair of disulfide bonds to improve stability and/or expression level.
- the antibody comprises a first antigen-binding moiety in one arm and a second antigen-binding moiety in the other arm, both in Fab format and operably linked to one chain of the immunoglobulin Fc region at the C terminus.
- the first antigen-binding moiety and the second antigen-binding moiety is intervened by the Fc region.
- the antibody may comprise a first antigen-binding moiety at one terminal of the Fc region which is a Fab, and a second antigen-binding moiety at the other terminal of the Fc region which is a Fab, scFv or VHH.
- the antibody in WuXiBody form comprises a first antigen-binding moiety operably linked to the second antigen-binding moiety, which is further operably linked to the Fc region.
- WO2019057122, WO2019057124 and WO2020057610 all of which incorporated herein by reference in its entirety.
- a native “T cell receptor” or a native “TCR” is a heterodimeric T cell surface protein which is associated with invariant CD3 chains to form a complex capable of mediating signal transduction.
- TCR belongs to the immunoglobulin superfamily, and is similar to a half antibody with a single heavy chain and a single light chain.
- a native TCR has an extracellular portion, a transmembrane portion, and an intracellular portion.
- the extracellular domain of a TCR has a membrane-proximal constant region and a membrane-distal variable region.
- Trastuzumab x Pertuzumab Pertuzumab
- Pertuzumab x Trastuzumab Trastuzumab
- Trastuzumab x Sacituzumab and “Sacituzumab x Trastuzumab” and similar designations, as used herein, are named following the same principle, i.e. refer to bispecific antibodies (preferably WuXiBody BsAbs) that comprise a first antigen binding moiety derived from the first antibody, and a second antigen-binding moiety derived from the second antibody.
- derived from it is meant that the variable regions are same as those in the parent antibody or have at least 80%homology (e.g.
- variable regions from parental antibodies may be humanized, affinity matured, or glycosylation modified before being constructed into the antibody format as disclosed herein.
- the methods for modification of the variable regions, including CDRs and framework regions, are familiar to a person in the art.
- the “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain.
- the heavy chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
- an “isolated antibody” is one which has been separated from a component of its natural environment.
- an antibody is purified to greater than 95%or 99%purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF) , capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) .
- electrophoretic e.g., SDS-PAGE, isoelectric focusing (IEF) , capillary electrophoresis
- chromatographic e.g., ion exchange or reverse phase HPLC
- a “disulfide bond” refers to a covalent bond with the structure R-S-S-R’.
- the amino acid cysteine comprises a thiol group that can form a disulfide bond with a second thiol group, for example from another cysteine residue.
- the disulfide bond can be formed between the thiol groups of two cysteine residues residing respectively on the two polypeptide chains, thereby forming an interchain bridge or interchain bond.
- transition metal refers to the elements of groups 4-12, justified by their typical chemistry, i.e. a large range of complex ions in various oxidation states, colored complexes, and catalytic properties either as the element or as ions (or both) .
- Sc and Y in Group 3 are also generally recognized as transition metals.
- the term “effective amount” used herein in relation to the metal ions refer to an amount of the metal ions that is sufficient to chelate with the disulfide bonds in the hinge region of the antibody and thus protect the disulfide bonds from reduction.
- the “effective amount” may be considered in the context of utilizing one or more metal ions, and a single metal ion may be considered as given in an effective amount if, in conjunction with one or more other metal ions, the desirable result is achieved.
- the effective amount of the metal ions can be empirically determined by a person skilled in the art based on the specific compositions and conditions used for conjugation. In some embodiments, the effective amount of metal ions in the reaction solution in step (a) is about 0.01 mM to 0.2 mM.
- DAR drug-to-Antibody Ratio
- PK pharmacokinetics
- Various analytical methods can be used to measure DAR, such as Ultraviolet-Visible (UV/Vis) spectroscopy, Hydrophobic interaction chromatography (HIC) , Reversed phase high-performance liquid chromatography (RP-HPLC) and Liquid chromatography coupled with electrospray ionization mass spectrometry (LC-ESI-MS) .
- UV/Vis Ultraviolet-Visible
- HIC Hydrophobic interaction chromatography
- RP-HPLC Reversed phase high-performance liquid chromatography
- LC-ESI-MS Liquid chromatography coupled with electrospray ionization mass spectrometry
- Hydrophobic interaction chromatography is a leading technique for the characterization of DAR values and drug loading distribution.
- the conjugated species are separated based on an increased hydrophobicity caused by the increased drug-load.
- cysteine-conjugated ADCs the unconjugated antibody with the least hydrophobicity is eluted first while the most hydrophobic, most drug conjugated form elutes last, generating a quantitative elution profile.
- the area percentage of a peak represents the relative amount of each drug-loaded ADC species.
- the payload distribution is derived from the HIC profile while the average DAR is also calculated from the percentage peak area.
- the ADCs conjugated by the process as disclosed herein are highly homogeneous.
- DAR2, DAR6 or DAR2+4 i.e. D2, D6, or D2+4 , depending on the specific processes used, can reach at least 80 wt%of total ADCs.
- DAR2+4 refers to a bi-drug ADC that comprises two molecules of the first drug and four molecules of the second drug per antibody.
- one antibody molecule belonging to IgG1 or IgG4 subclass has 4 inter-chain S-Sbonds, each of which is formed with two -SH groups.
- the antibody molecule can be subjected to partial or complete reduction of one or more interchain S-Sbonds to form 2n (n is an integer selected from 1, 2, 3 or 4) reactive -SH groups, and thus, the number of drugs coupling to a single antibody molecule is 2, 4, 6 or 8.
- the different conjugates containing different number of drug molecules are denominated as D0, D2, D4, D6 and D8.
- D2 refers to the ADC in which two drug molecules are coupled to one single antibody molecule, where two drug molecules may be coupled to -SH groups generated by reduction of S-Sbonds between heavy and light chains via linkers, or may be coupled to -SH groups generated by reduction of S-Sbonds between heavy and heavy chains via linkers.
- D4 refers to the ADC in which four drug molecules are coupled to one single antibody molecule, where four drug molecules may be coupled to four -SH groups generated by reduction of two S-Sbonds between heavy and light chains, or between heavy and heavy chains via linkers, or two drug molecules may be coupled to two -SH groups generated by reduction of one S-Sbond between heavy and light chains via linkers and the other two drug molecules may be coupled to two -SH groups generated by reduction of one S-Sbond between heavy and heavy chains vis linkers.
- D6 refers to the ADC in which six drug molecules are coupled to one single antibody molecule, where four drug molecules may be coupled to four -SH groups generated by reduction of two S-Sbonds between heavy and light chains via linkers and two drug molecules may be coupled to two -SH groups generated by reduction of one S-Sbonds between heavy and heavy chains via linkers, or four drug molecules may be coupled to four -SH groups generated by reduction of two S-Sbonds between heavy and heavy chains via linkers and two drug molecules may be coupled to two -SH groups generated by reduction of one S-Sbonds between heavy and light chains via linkers.
- D8 refers to the ADC in which eight drug molecules are coupled to one single antibody molecule, i.e., all the four S-Sbonds in one antibody molecule are reduced to eight -SH groups and each -SH group attaches one drug molecule.
- the heterogeneous mixture of ADC molecules generated by conventional conjugation processes or the bio-conjugation process of the present disclosure is a mixture of D0, D2, D4, D6 and D8.
- the term “homogeneity” of antibody-drug conjugates is used to describe the property of dominance of one specific type of antibody-drug conjugate (preferably, one type selected from D2, D4, D6 conjugates) in one given mixture of antibody-drug conjugates.
- the “homogeneity” of antibody-drug conjugates refers to a high level of one specific type of ADC in the mixture of antibody-drug conjugates.
- pharmaceutically acceptable indicates that the designated carrier, vehicle, diluent, excipient (s) , and/or salt is generally chemically and/or physically compatible with the other ingredients comprising the formulation, and physiologically compatible with the recipient thereof.
- a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is bioactivity acceptable and nontoxic to a subject.
- Pharmaceutical acceptable carriers for use in the pharmaceutical compositions disclosed herein may include, for example, pharmaceutically acceptable liquid, gel, or solid carriers, aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, anesthetics, suspending/dispending agents, sequestering or chelating agents, diluents, adjuvants, excipients, or non-toxic auxiliary substances, other components known in the art, or various combinations thereof.
- subject includes any human or nonhuman animal, for example, humans.
- cancer refers to any tumor or a malignant cell growth, proliferation or metastasis-mediated, solid tumors and non-solid tumors such as leukemia and initiate a medical condition.
- a “tumor” comprises one or more cancerous cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastema, sarcoma, and leukemia or lymphoid malignancies.
- cancers include squamous cell cancer (e.g., epithelial squamous cell cancer) , lung cancer including small-cell lung cancer, non-small cell lung cancer ( “NSCLC” ) , adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.
- squamous cell cancer e.g., epithelial squamous cell cancer
- lung cancer including small-cell lung cancer, non-small cell lung cancer ( “NSCLC”
- treatment refers generally to treatment and therapy, whether of a human or an animal, in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, regression of the condition, amelioration of the condition, and cure of the condition.
- Treatment as a prophylactic measure i.e., prophylaxis, prevention
- treating may refer to dampen or slow the tumor or malignant cell growth, proliferation, or metastasis, or some combination thereof.
- treatment includes removal of all or part of the tumor, inhibiting or slowing tumor growth and metastasis, preventing or delaying the development of a tumor, or some combination thereof.
- Antibody-drug conjugates are usually produced by two conventional chemical strategies, Lysine based conjugation and Cysteine from the reduction of interchain sulfide bonds based conjugation.
- conjugation based on Cysteine from the reduction of interchain sulfide bonds it comprises a step of opening inter-chain disulfide bonds in the presence of various reductants, such as TCEP, DTT and so on, followed by nucleophilic reaction of thiol groups.
- antibody-drug conjugates are typically formed by conjugating one or more antibody cysteine thiol groups to one or more linker moieties bound to a drug thereby forming an antibody-linker-drug complex.
- the number of drugs coupling to a single antibody molecule is an important factor for the efficacy and safety of the resultant ADC.
- the inter-chain S-Sbonds are more accessible to solvents than other disulfide bonds. Therefore, the inter-chain disulfide bonds can be used as the binding sites for coupling a drug (or a drug-linker) to an antibody.
- one therapeutic antibody molecule belonging to IgG1 or IgG4 subclass has 4 inter-chain S-Sbonds, each of which is formed with two -SH groups, and thus, the number of drugs coupling to a single antibody molecule is 2, 4, 6 or 8.
- D0 the product is referred to as D0.
- D2 refers to the ADC in which two drug molecules are coupled to one single antibody molecule.
- D4 refers to the ADC in which four drug molecules are coupled to one single antibody molecule.
- D6 refers to the ADC in which six drug molecules are coupled to one single antibody molecule.
- D8 refers to the ADC in which eight drug molecules are coupled to one single antibody molecule, i.e., all the four S-Sbonds in one antibody molecule are reduced to eight -SH groups and each -SH group attaches one drug molecule.
- the heterogeneous mixture of ADC molecules generated by conventional conjugation processes is a mixture of D0, D2, D4, D6 and D8.
- heterogeneous ADC products are generally of lower efficacy and unsatisfactory PK properties.
- D0 has no ADC efficacy, and due to their hydrophobicity induced from payload (i.e., drug) molecules, D8 is considered to be the reason of instability in the circulation.
- payload i.e., drug
- antibody-drug conjugate potency in vitro has been shown to be directly dependent on drug loading (Hamblett KJ, et al., Clin Cancer Res.
- in-vivo antitumor activity of antibody-drug conjugates with four drugs per molecule was comparable with conjugates with eight drugs per molecule (D8) at equal mAb doses, even though the conjugates contained half the amount of drugs per mAb.
- Drug-loading also affected plasma clearance, with D8 conjugate being cleared 3-fold faster than D4 conjugate and 5-fold faster than a D2 conjugate.
- Antibody-drug conjugates with improved homogeneity provide benefits in therapy, for example a higher therapeutic index, improving efficacy and reducing toxicity of the drug.
- Homogeneous antibody conjugates also provide more accurate and consistent measurements in diagnostic and imaging applications.
- the drug-loading of an ADC may be controlled in different ways, e.g., by: (i) limiting the molar excess of drug-linker intermediate or linker reagent relative to antibody, (ii) limiting the conjugation reaction time or temperature, (iii) partial or limiting reductive conditions for cysteine thiol modification, (iv) engineering by recombinant techniques the amino acid sequence of the antibody such that the number and position of cysteine residues is modified for control of the number and/or position of linker-drug attachments (such as thioMab or thioFab and those disclosed in WO2006/034488, herein incorporated by reference in its entirety) .
- linker-drug attachments such as thioMab or thioFab and those disclosed in WO2006/034488, herein incorporated by reference in its entirety
- the present disclosure provides a method or process for preparing highly homogeneous ADCs for antibodies.
- the antibodies comprise an engineered Fab whose CH1 and CL domains are replaced by a pair of T cell receptor (TCR) constant regions, and the pair of TCR constant regions is capable of forming a non-native interchain disulfide bond.
- This disulfide bond is capable of stabilizing the dimer formed between the pair of TCR constant regions, and as described above, is less accessible to solvents or reductants than native disulfide bonds.
- the antibodies to be conjugated herein are constructed via Platform and also named as “WuXiBody” .
- a “WuXiBody” is generally a bispecific (or multispecific) antibody that comprises a first and second antigen-binding moiety, the first antigen-binding moiety is an engineered Fab comprising a first heavy chain variable domain (VH) operably linked to a first T cell receptor (TCR) constant region (C1) , and a first light chain variable domain (VL) operably linked to a second TCR constant region (C2) , while the second antigen-binding moiety may be in Fab, scFv, VHH format, among others.
- the second antigen-binding moiety is also in Fab format and comprises a second VH operably linked to an antibody heavy chain CH1 domain, and a second VL operably linked to an antibody light chain constant (CL) domain.
- the commonly present CH1 domain and CL domain are replaced by a pair of TCR constant regions, thus the native disulfide bond between CH1 domain and CL domain is also replaced by one or more engineered non-native disulfide bond (s) between the TCR C1 and C2 regions.
- the positions of C1 and C2 regions can also be exchanged.
- the antibodies to be conjugated herein are not limited to bispecific antibodies that have the first and second antigen-binding moieties targeting different epitopes or antigens.
- the antibodies to be conjugated herein could also be monospecific antibodies wherein the first and second antigen-binding moieties bind to a same antigen or epitope, and the resultant ADCs are highly homogenous ADCs against a single antigen or epitope.
- the antibody comprises the following structure: in the 1 st heavy chain, VH1-C1-hinge-Fc; in the 2 nd heavy chain, VH2-CH1-hinge-Fc; in the 1 st light chain, VL1-C2; and in the 2 nd light chain, VL2-CL, wherein VH1 and VL1 refer to the first VH and VL and VH2 and VL2 refer to the second VH and VL, respectively.
- “-” represents an operable linkage, generally via a peptide linker.
- the WuXiBody may adopt various other formats.
- the heavy chain portion of the first antigen binding moiety may be operably linked to the second antigen binding moiety, and the latter one is further operably linked to one chain of the Fc region.
- the heavy chain portion of the first antigen binding moiety is operably linked to one chain of the Fc region, and the latter one is further operably linked to one chain of the second antigen binding moiety.
- the antibody comprises the following structure: in the 1 st heavy chain, VH1-C1-hinge-Fc-scFv; in the 2 nd heavy chain, VH1-CH1-hinge-Fc-scFv; in the 1 st light chain, VL1-C2; and in the 2 nd light chain, VL1-CL.
- the scFv belongs to the second antigen-binding moiety and can also be replaced by a VHH format.
- the first TCR constant region and the second TCR constant region are associated via a non-native interchain disulfide bond.
- the pair of TCR constant regions in the first antigen-binding moiety includes TCR alpha and beta constant regions (wild-type or preferably engineered) in the light chain and heavy chain respectively.
- the TCR constant regions in the bispecific antibodies are capable of associating with each other to form a dimer through a non-native disulfide bond.
- TCR beta chain constant region has two different variants, known as TRBC1 and TRBC2 (IMGT nomenclature) .
- TRBC1 Human TCR beta chain constant region
- TRBC2 IMGT nomenclature
- the pair of TCR constant regions comprises an engineered TCR beta domain comprising one or more mutated sites, as shown below:
- TRAC Human TCR alpha chain constant region
- P01848 https: //www. uniprot. org/uniprot/P01848
- sequence of wild type TCR alpha domain is:
- the pair of TCR constant regions comprises an engineered TCR alpha chain constant region comprising one or more mutated sites, as shown below:
- the antibody for preparing ADCs as disclosed herein may comprise a variety of C1 and C2 regions, as long as they can stabilize the first VH and VL regions to form the first antigen-binding moiety.
- the antibodies may comprise a TCR C1 region with the amino acid sequence as shown in SEQ ID No: 2 or 7 or a variant thereof with at least 90%identity, and a TCR C2 region with the amino acid sequence as shown in SEQ ID No: 4, 8, 9 or a variant thereof with at least 90%identity. More than one pair of non-native disulfide bonds can be formed between the C1 and C2 regions to improve stability and expression level.
- the variants of SEQ ID No: 2 or 7 comprise substitutions, additions and/or deletions of one or more amino acids compared to SEQ ID No: 2 or 7.
- the variants of SEQ ID No: 4, 8, or 9 comprise substitutions, additions and/or deletions of one or more amino acids compared to SEQ ID No: 4, 8, or 9.
- the antibodies comprise a combination of C1 and C2 regions with SEQ ID Nos: 2 and 4 (for cAb1-6) , or with SEQ ID Nos: 2 and 8 (for cAb7) , or with SEQ ID Nos: 7 and 9 (for cAb8) , respectively.
- the native TCR beta chain contains a native cysteine residue at position 76, which is unpaired and therefore does not form a disulfide bond in a native alpha/beta TCR.
- this native cysteine residue at position 76 of TCR beta chain is mutated to an alanine residue. This may be useful to avoid incorrect intrachain or interchain pairing.
- the substitution in certain embodiments can improve the TCR refolding efficiencies in vitro.
- the first and the second TCR constant regions of the first antigen-binding moiety are capable of forming a dimer comprising, between the TCR constant regions (i.e., CAlpha and CBeta) , at least one non-native interchain disulfide bond that is capable of stabilizing the dimer.
- TCR constant regions i.e., CAlpha and CBeta
- the benefits provided by replacing CH1 and CL domains with TCR constant regions is significant.
- the first antigen-binding moiety with at least one non-native disulfide bond can be recombinantly expressed and assembled into the desired conformation, which stabilizes the TCR constant region dimer while providing for good antigen-binding activity of the antibody variable regions.
- the first antigen-binding moiety is found to well tolerate routine antibody engineering, for example, modification of glycosylation sites, and removal of some natural sequences.
- the bispecific antibodies in such format can be readily expressed and assembled with minimal or substantially no mispairing of the antigen-binding sequences due to the presence of the TCR constant regions in the first antigen-binding moiety.
- the non-native disulfide bond in the TCR constant regions is less accessible to solvents than native disulfide bonds, thereby providing fewer binding sites (and improved homogeneity) for coupling a drug (or a drug-linker) .
- the non-native disulfide bonds are possibly less sensitive to reductants than native disulfide bonds.
- the process comprises constructing the antibody based on a parental bispecific antibody or two parental monospecific antibodies and generation of the antibody, prior to step (a) .
- based on it is meant to derive or obtain the first and second VH and VL regions from the variable regions of the parental antibodies and assemble into the WuxiBody format with other regions e.g. TCR constant regions, heavy and light chain constant regions, hinge regions and Fc regions.
- the BsAbs to be used for conjugation comprise two antigen-binding moieties which may be a Fab, Fab’, scFv, VHH etc.
- the antigen-binding moiety may be derived from an antibody (already known or developed de novo) targeted to a certain antigen.
- the first antigen-binding moiety is derived from Trastuzumab and the second antigen-binding moiety is derived from Pertuzumab, or vice versa.
- the first antigen-binding moiety is derived from Trastuzumab and the second antigen-binding moiety is derived from Sacituzumab, or vice versa.
- the antigen-binding moiety comprises the CDR sequences of the parent antibody, and preferably, comprises the variable regions of the parent antibody. In some embodiments, the antigen-binding moiety comprises the variants of the CDR sequences of the parent antibody which retain the antigen-binding specificity.
- the parent antibodies that can derive the antigen-binding moieties can include all monoclonal antibodies that have specificity for a certain antigen, such as antibodies against tumor related antigens or pathways, e.g. PD-1/PD-L1, TIM-3, LAG-3, VEGF, HER2, CTLA-4, BMPR1B, E16, STEAP1, MUC16, MPF, Napi2b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, HER2, NCA, MDP, IL20Ra, Brevican, EphB2R, ASLG659, PSCA, GEDA, BAFF-R, CD22, CD79a, CXCR5, HLA-DOB, P2X5, CD72, LY64, FcRH1, FcRH5, TENB2, PMEL17, TMEFF1, GDNF-Ra1, Ly6
- the antibodies may include but not limited to, trastuzumab, pertuzumab, sacituzumab, abciximab, adalimumab, alefacept, alemtuzumab, basiliximab, belimumab, bezlotoxumab, canakinumab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, golimumab, inflectra, ipilimumab, ixekizumab, natalizumab, nivolumab, olaratumab, omalizumab, palivizumab, panitumumab, pembrolizumab, rituximab, tocilizumab, trastuzumab, secukinumab, and ustekinumab.
- the bispecific antibody used in the method provided herein may be antibodies that have binding specificity for a numerous variety of antigens, such as tumor associated antigens (TAA) .
- TAA tumor associated antigens
- the bispecific antibodies to be conjugated have a first specificity for a first TAA antigen, and a second specificity for a second TAA antigen.
- TAA tumor associated antigen
- the term “tumor associated antigen” refers to a target antigen expressed by tumor cells, however may be expressed by the cognate cell (or healthy cells) prior to transforming into a tumor.
- the tumor associated antigens can be presented only by tumor cells and not by normal, i.e. non-tumor cells.
- the tumor associated antigens can be exclusively expressed on tumor cells or may represent a tumor specific mutation compared to non-tumor cells. In some other embodiments, the tumor associated antigens can be found in both tumor cells and non-tumor cells, but is overexpressed on tumor cells when compared to non-tumor cells or are accessible for antibody binding in tumor cells due to the less compact structure of the tumor tissue compared to non-tumor tissue. In some embodiments, the tumor associated antigen is located on the vasculature of a tumor.
- Illustrative examples of a tumor associated antigen are LAG-3, CD10, CD19, CD20, CD22, CD21, CD22, CD25, CD30, CD33, CD34, CD37, CD44v6, CD45, CD133, Fms-like tyrosine kinase 3 (FLT-3, CD135) , chondroitin sulfate proteoglycan 4 (CSPG4, melanoma-associated chondroitin sulfate proteoglycan) , Epidermal growth factor receptor (EGFR) , Her2neu, Her3, IGFR, IL3R, fibroblast activating protein (FAP) , CDCP1, Derlin1, Tenascin, frizzled 1-10, the vascular antigens VEGFR2 (KDR/FLK1) , VEGFR3 (FLT4, CD309) , PDGFR-alpha (CD140a) , PDGFR-beta (CD140b) Endoglin, CLEC14, Te
- Further examples may include A33, CAMPATH-1 (CDw52) , Carcinoembryonic antigen (CEA) , Carboanhydrase IX (MN/CA IX) , de2-7 EGFR, EGFRvIII, EpCAM, Ep-CAM, Folate-binding protein, G250, Fms-like tyrosine kinase 3 (FLT-3, CD135) , c-Kit (CD117) , CSF1R (CD115) , HLA-DR, IGFR, IL-2 receptor, IL3R, MCSP (Melanoma-associated cell surface chondroitin sulphate proteoglycane) , Muc-1, Prostate-specific membrane antigen (PSMA) , Prostate stem cell antigen (PSCA) , Prostate specific antigen (PSA) , and TAG-72.
- CAMPATH-1 CDw52
- CEA Carcinoembryonic antigen
- MN/CA IX Car
- the bispecific antibodies provided herein have a first specificity for a TAA antigen, and a second specificity for an infectious disease-associated antigen or an epitope thereof.
- infectious disease-associated antigens include, e.g., an antigen that is expressed on the surface of a virus particle, or preferentially expressed on a cell that is infected with a virus, wherein the virus is selected from the group consisting of HIV, hepatitis (A, B or C) , herpes virus (e.g., HSV-1 , HSV-2, CMV, HAV-6, VZV, Epstein Barr virus) , adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV, dengue virus, papillomavirus, molluscum
- the target antigen can be an antigen that is expressed on the surface of a bacterium, or preferentially expressed on a cell that is infected with a bacterium, wherein the bacterium is selected from the group consisting of chlamydia, rickettsia, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci, gonococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospira, and Lyme disease bacteria.
- the bacterium is selected from the group consisting of chlamydia, rickettsia, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci, gonococci, klebsiella, proteus, serratia
- the target antigen is an antigen that is expressed on the surface of a fungus, or preferentially expressed on a cell that is infected with a fungus, wherein the fungus is selected from the group consisting of Candida (albicans, krusei, glabrata, tropicalis, etc. ) , Crytococcus neoformans, Aspergillus (fumigatus, niger, etc. ) , Mucorales (mucor, absidia, rhizopus, etc.
- the target antigen is an antigen that is expressed on the surface of a parasite, or preferentially expressed on a cell that is infected with a parasite, wherein the parasite is selected from the group consisting of Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, Nippostrongylus brasiliensis, Taenia crassiceps,
- Non-limiting examples of specific pathogen-associated antigens include, e.g., HIV gp120, HIV CD4, hepatitis B glucoprotein L, hepatitis B glucoprotein M, hepatitis B glucoprotein S, hepatitis C E1, hepatitis C E2, hepatocyte-specific protein, herpes simplex virus gB, cytomegalovirus gB, and HTLV envelope protein.
- the WuXiBody BsAb to be conjugated herein may further comprise a knob-into-hole structure in the Fc region.
- An extra inter-chain disulfide bond is created in the knob-hole region to increase the stability of the bispecific antibody.
- the other 2 pairs of non-native disulfide bonds (in the TCR region and Fc region) are structurally not exposed to reducing agent and thus cannot be opened for drug attachment. In the circumstances where C1 and C2 regions form more than one non-native disulfide bonds, they are also structurally inaccessible to reducing agents.
- the bispecific antibodies to be conjugated herein comprise two heavy chains and two light chains, wherein from N terminal to C terminal:
- the first heavy chain comprises domains operably linked as in VH1-C1-hinge-Fc and the first light chain comprises domains operably linked as in VL1-C2;
- the second heavy chain comprises domains operably linked as in VH2-CH1-hinge-Fc and the second light chain comprises domains operably linked as in VL2-CL, wherein VH1 and VL1 refer to the first heavy chain and light chain variable regions derived from a first parental antibody, while VH2 and VL2 refer to the second heavy chain and light chain variable regions derived from a first parental antibody.
- VH1, C1, VL1 and C2 constitute the first antigen binding moiety
- VH2, CH1, VL2 and CL constitute the second antigen binding moiety.
- the disclosure provides a process for preparing a highly homogeneous (occupies more than 50%, 60%, 70%, 80%, 90%or higher of total produced ADCs) antibody-drug conjugate (ADC) for the bispecific antibody as described above, the process comprises the following steps:
- step (b) introducing an excess amount of a linker-drug moiety (e.g. MC-MMAF) to react with reduced thiol groups resulted from step (a) ; and
- a linker-drug moiety e.g. MC-MMAF
- the process further comprises adding an effective amount of oxidant to re-oxidize the unreacted thiol groups after step (b) .
- the bispecific antibody to be conjugated is constructed as a knob-into-hole bispecific antibody with a TCR arm and a normal IgG Fab at its variable regions.
- An extra inter-chain disulfide bond is created in the knob-hole region to increase the stability of the bispecific antibody.
- drugs e.g. maleimide-modified drug
- D6 D2
- Two pairs of non-native disulfide bonds, one in the TCR constant regions and the other in the “knob-hole” structure, are not reduced by the reductant, which leaves only 3 pairs of disulfide bonds for reduction and site-specific conjugation.
- two pairs are in the hinge region and the other pair is in the CH1-CL region of the second antigen-binding moiety.
- the content of D6 ADCs can reach at least 80 wt%, for example, at least 85 wt%, at least 90 wt%, at least 91 wt%, at least 92 wt%or at least 93 wt%, on the basis of total weight of D0, D2, D4 and D6, as measured by HIC.
- the reductant may be TCEP.
- the concentration of the reductant in the reaction solution may be 0.04 mM to 0.4 mM.
- the oxidant to be added may be DHAA.
- the concentration of the oxidant in the reaction solution may be 0.08 mM to 0.8 mM.
- the optimum pH for the reaction will typically be between about 5.5 and about 8, for instance, about 5.5 to 7.5.
- the optimal reaction conditions will of course depend upon the specific reactants employed.
- the buffer is PBS, pH 7.
- the optimum temperature for the reduction reaction and conjugation reaction will typically be between about -10°C and 37°C, e.g. about 4°C-22°C.
- the reduction reaction occurs at a temperature of about 22°C for 8-18 h
- the conjugation reaction occurs at a temperature of about 4°C overnight.
- the temperature and time may vary depending on the amounts of antibody, reductant and drugs used.
- step (a) depend on specific antibodies to be conjugated.
- the determination of the incubation time period and temperature based on specific antibodies is within the abilities of ordinary skilled persons in the art.
- the antibody to be conjugated is typically incubated with the reductant at 4°C overnight.
- the concentration of the bispecific antibody in the reaction is from 0.01 mM to 0.1 mM. In a specific embodiment, the concentration of the antibody is 0.02 mM.
- step (c) those skilled in the art can select proper purification methods to recover the resultant antibody-drug conjugates.
- Many ADC purification methods are well known in the art.
- the resultant antibody-drug conjugates may be purified by using a de-salting column, size exclusion chromatography, and the like.
- the resultant antibody-drug conjugates are recovered by any suitable purification method, such as using a de-salting column, size exclusion chromatography, ultrafiltration, dialysis, UF-DF, and the like.
- Transitional metal ions and/or divalent metal ions could protect the disulfide bonds in the hinge region from being reduced during the incubation of the reductant and the antibody.
- the inventors herein combined such metal ion chelating function with WuXiBody antibody for ADC conjugation, giving very narrow DAR2 distribution which allows the preparation of ADCs of low DAR.
- drugs such as PBD
- ADCs of low DAR are desired.
- the disclosure provides a process for preparing an antibody-drug conjugate (ADC) for the bispecific antibody as described above, wherein the process comprises the following steps:
- step (b) introducing an excess amount of a linker-drug moiety (e.g. MC-MMAF) to react with reduced thiol groups resulted from step (a) ; and
- a linker-drug moiety e.g. MC-MMAF
- the process further comprises adding an effective amount of oxidant to re-oxidize the unreacted thiol groups after step (b) .
- the reductant may be TCEP.
- the concentration of the reductant in the reaction solution may be 0.04 mM to 0.4 mM.
- the oxidant to be added after step (b) may be DHAA.
- the concentration of the oxidant in the reaction solution may be 0.08 mM to 0.8 mM.
- the metal ion which is suitable to be used in the bio-conjugation process of the present disclosure is selected from transition metal ions and divalent ions, including but not limited to, Zn2+, Cd2+, Ca2+, Mg2+ and Hg2+, and the like.
- Zn2+ is used due to its easy availability and low cost.
- suitable transition metal salts may be added in step (a) as long as they are soluble in the reaction solution so that free transition metal ions can be released in the reaction solution.
- ZnCl2, Zn (NO3) 2, ZnSO4, Zn (CH3COO) 2, ZnI2, ZnBr2, Zinc Formate, and zinc tetrafluoroborate may be mentioned as suitable zinc salts.
- other transition metal salts which are soluble and can release free Cd2+ or Hg2+ ions in the reaction solution can be mentioned, which include, but not limited to, CdCl2, Cd (NO3) 2, CdSO4, Cd (CH3COO) 2, CdI2, CdBr2, cadmium formate, and cadmium tetrafluoroborate; HgCl2, Hg(NO3) 2, HgSO4, Hg (CH3COO) 2, HgBr2, Mercury (II) formate, and Mercury (II) tetrafluoroborate; and the like.
- Those skilled in the art can make a selection from the above transition metal salts and divalent metal salts as the source of metal ions.
- Zn2+ is used in step (a) .
- Zinc salts which are water soluble are available.
- ZnCl2 may be added in step (a) as the Zn2+ source.
- the concentration of the metal ions in the reaction solution in step (a) is 0.01 mM to 0.2 mM.
- the metal ions will be removed in purification step by using EDTA as chelating reagent, which will be filtered out in subsequent dialysis, ultrafiltration or gel filtration.
- buffer system for the reaction in step (a) , including, but not limited to, Hepes, Histidine buffer, PBS, MES, and the like.
- the buffer system used in step (a) is PBS.
- the optimum pH for the reaction will typically between about 5.5 and about 8, for instance, about 5.5 to 7.5.
- the optimal reaction conditions will of course depend upon the specific reactants employed.
- the buffer is PBS, pH 7.
- the optimum temperature for the reduction reaction and conjugation reaction will typically be between about -10°C and 37°C, e.g. about 4°C-22°C.
- the reduction reaction occurs at a temperature of about 4°C overnight
- the conjugation reaction occurs at a temperature of about 4°C for 2-8 h.
- the temperature and time may vary depending on the amounts of antibody, reductant and drugs used.
- the antibody to be conjugated, the metal ions and the reductant may be present in the reaction mixture in a ratio of 1: 2: 4 in molar concentration.
- 0.02 mM antibody is incubated with 0.08 mM TCEP and 0.04 mM ZnCl2 at 4°C overnight.
- a molar concentration may also be converted into “eq” compared to antibody.
- “0.04 mM ZnCl2” may be converted into “2 eq ZnCl2” if antibody is used at 0.02 mM.
- the content of D2 ADCs can reach at least 80 wt%, for example, at least 85 wt%, at least 90 wt%, at least 91 wt%, at least 92 wt%, at least 93 wt%, at least 94 wt%, or at least 95 wt%on the basis of total weight of D0 and D2, as measured by HIC.
- ADC ADC-associated drug resistance
- the present disclosure provides a process for producing highly homogeneous (more than 50%, 60%, 70%, 80%, 90%or higher of total produced ADCs) ADCs with two different payloads.
- the disclosure provides a process for preparing an antibody-drug conjugate (ADC) of the bispecific antibodies as described above, wherein the process comprises the following steps:
- step (b) introducing an excess amount of a first linker-drug moiety to react with reduced thiol groups resulted from step (a) ;
- step (c) removing the metal ions from the product of step (b) ;
- the process further comprises adding an effective amount of oxidant to re-oxidize the unreacted thiol groups after step (d) .
- the reductant, metal ions, buffer systems and oxidants may be the same as disclosed above for preparing D2 ADC.
- the metal ions can be removed in purification step by using EDTA as chelating reagent, which will be filtered out in subsequent dialysis, ultrafiltration or gel filtration.
- the reaction conditions for reducing and conjugation may be the same as disclosed above for preparing D2 ADC.
- the optimum temperature for the reduction reaction and conjugation reaction will typically be between about -10°C and 37°C, e.g. about 4°C-22°C.
- the second reduction and conjugation of steps (c) and (d) may have slight differences from steps (a) and (b) .
- the reduction reaction for step (c) occurs at a temperature of about 22°C for 2-8h
- the conjugation reaction occurs at about 22°C for 2-8 h.
- the temperature and time may vary depending on the amounts of antibody, reductant and drugs used.
- the first linker-drug moiety is MC-MMAF and the second linker-drug moiety is MC-DXD or DXD with other linkers.
- the content of D2+4 ADCs can reach at least 80 wt%, for example, at least 85 wt%, at least 90 wt%, at least 91 wt%, at least 92 wt%, at least 93 wt%, at least 94 wt%, or at least 95 wt%on the basis of total weight of D0, D2, D2+2 and D4, as calculated from MS analysis.
- ADC ADC molecules of such a mixture not only brings difficulties in analysis and characterization, but also potentially has different pharmacokinetic, distribution, toxicity and efficacy profiles. And non-specific conjugation also frequently results in impaired antibody function. Therefore, narrow distribution of DAR is desired for better PK, efficacy and therapeutic window.
- the present disclosure provides a highly homogeneous antibody-drug conjugates of bispecific antibodies, wherein the D6 ADC constitute more than 80 wt%of the ADCs.
- the present disclosure provides a highly homogeneous antibody-drug conjugates of bispecific antibodies, wherein the D2 ADC constitute more than 80 wt%of the ADCs.
- the present disclosure provides a highly homogeneous antibody-drug conjugates of bispecific antibodies, wherein the D2+4 ADC constitute more than 80 wt%of the ADCs.
- the homogeneity of the antibody-drug conjugates generated by the process as disclosed herein is measured and compared with the homogeneity of corresponding control antibody-drug conjugates generated by conventional conjugation processes.
- HIC is the analytical method used to determine yields and isomeric mixtures from resultant antibody-drug conjugates (e.g., for D6 conjugates) .
- This technique is able to separate antibodies loaded with various numbers of drugs.
- the drug loading level can be determined based on the ratio of absorbances, e.g., at 250 nm and 280 nm. For example, if a drug can absorb at 250 nm while the antibody absorbs at 280 nm. The 250/280 ratio therefore increases with drug loading.
- Using the bio-conjugation process described herein generally antibodies with even numbers of drugs were observed because conjugation incompletion leads to even number of DAR.
- antibody-drug conjugates for local delivery of cytotoxic or cytostatic agents, i.e. drugs to kill or inhibit tumor cells in the treatment of cancer allows targeted delivery of the drug moiety to tumors, and intracellular accumulation therein, where systemic administration of unconjugated drug agents may result in unacceptable levels of toxicity to normal cells as well as the tumor cells sought to be eliminated (Thorpe, (1985) "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review, " in Monoclonal Antibodies '84: Biological And Clinical Applications, A. Pinchera et al. (ed. s) , pp. 475-506) . Both polyclonal antibodies and monoclonal antibodies have been reported as useful in these strategies (Rowland et al., (1986) Cancer Immunol. Immunother., 21: 183-87) .
- Drugs that can be used in ADCs include chemotherapeutic agents such as daunomycin, doxorubicin, methotrexate, and vindesine; toxins, for example bacterial toxins such as diphtheria toxin, plant toxins such as ricin, small molecule toxins such as geldanamycin, maytansinoids, and calicheamicin; auristatin peptides, auristatin E (AE) and monomethylauristatin (MMAE) , which are synthetic analogs of dolastatin.
- MMAE is a synthetic derivative of dolastatin 10, a natural cytostatic pseudo peptide.
- the toxins may achieve their cytotoxic and cytostatic effects by mechanisms including tubulin binding, DNA binding, or topoisomerase inhibition. Some cytotoxic drugs tend to be inactive or less active when conjugated to large antibodies or protein receptor ligands.
- the drug and linker which can be used in the conjugation process of the present disclosure, as long as the drug molecule has an antitumor, antiviral or antimicrobial effect and contains at least one substituted group or a partial structure allowing connection to a linker structure, and the linker contains at least two reactive groups, one of which can covalently bond a drug molecule and the other of which can covalently couple to an antibody.
- the linker is susceptible to –SH attack from the antibody and capable of forming a linkage with the antibody.
- a drug-maleimide complex i.e., maleimide linking drug
- a drug-maleimide complex is taken as an example of the payload bearing reactive group in the present disclosure.
- the drug may include, but not limited to, cytotoxic reagents, such as chemo-therapeutic agents, immunotherapeutic agents and the like, antiviral agents or antimicrobial agents.
- the drug to be conjugated with an antibody may be selected from, but not limited to, MMAE (monomethyl auristatin E) , MMAD (monomethyl auristatin D) , MMAF (monomethyl auristatin F) , and the like.
- Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, non-binding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa) , ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S) , momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
- diphtheria A chain non-binding active fragments of diphtheria toxin
- exotoxin A chain from Pseudomonas aeruginosa
- ricin A chain abrin A chain
- radionuclides are available for the production of radioconjugated antibodies. Examples include 212Bi, 131I, 131In, 90Y, and 186Re.
- One or more small molecule toxins such as a calicheamicin, maytansinoids, dolastatins, auristatins, a trichothecene, and CC1065, and the derivatives of these toxins that have toxin activity, can be conjugated with the antibody by the process as disclosed herein.
- Maytansine compounds suitable for use as maytansinoid drug moieties are well known in the art and can be isolated from natural sources according to known methods, produced using genetic engineering techniques (see Yu et al (2002) PNAS 99: 7968-7973) , or maytansinol and maytansinol analogues prepared synthetically according to known methods. Suitable maytansinoids are disclosed, for example, in U.S. Patent No. 5,208,020. Preferred maytansinoids are maytansinol and maytansinol analogues modified in the aromatic ring or at other positions of the maytansinol molecule, such as various maytansinol esters.
- Dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cellular division and have anticancer and antifungal activity (Pettit et al (1998) Antimicrob. Agents Chemother. 42: 2961-2965) .
- the dolastatin or auristatin drug moiety may be attached to the antibody through the N (amino) terminus or the C (carboxyl) terminus of the peptidic drug moiety (WO 02/088172) .
- Exemplary embodiments comprising MMAE or MMAF and various linker components are shown below.
- VcMMAE (Mc-vc-PAB-MMAE) is obtained by using MMAE linked via p-aminobenzyloxycarbonyl ( “PAB” ) to the lysosomally cleavable dipeptide valine-citrulline (vc) and a thiolreactive maleimidocaproyl spacer (MC) .
- PAB p-aminobenzyloxycarbonyl
- MC thiolreactive maleimidocaproyl spacer
- Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3- (2-pyridyldithiol) propionate (SPDP) , iminothiolane (IT) , bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl) , active esters (such as disuccinimidyl suberate) , aldehydes (such as glutaraldehyde) , bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine) , bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl) -ethylenediamine) , diisocyanates (such as toluene 2, 6-diisocyanate) , and bis-active fluorine compounds (such as 1, 5-difluoro-2, 4-dinitrobenzene
- a ricin immunotoxin can be prepared as described in Vitetta et al (1987) Science, 238: 1098.
- Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody (WO94/11026) .
- VcMMAE (Mc-vc-PAB-MMAE) is obtained by using MMAE linked via p-aminobenzyloxycarbonyl ( “PAB” ) to the lysosomally cleavable dipeptide valine-citrulline (vc) and a thiolreactive maleimidocaproyl spacer (MC) .
- PAB p-aminobenzyloxycarbonyl
- the present disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of the ADCs with improved homogeneity prepared by the process as disclosed herein and a pharmaceutically acceptable carrier or vehicle.
- the compositions are suitable for veterinary or human administration.
- compositions of the present disclosure can be in any form that allows for the composition to be administered to an animal.
- the composition can be in the form of a solid, liquid or gas (aerosol) .
- routes of administration include, without limitation, oral, topical, parenteral, sublingual, rectal, vaginal, ocular, and intranasal.
- Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
- the compositions are administered parenterally.
- Pharmaceutical compositions of the invention can be formulated so as to allow ADCs of the disclosure to be bioavailable upon administration of the composition to an animal.
- Compositions can take the form of one or more dosage units, where for example, a tablet can be a single dosage unit, and a container of ADCs of the disclosure in aerosol form can hold a plurality of dosage units.
- compositions can be non-toxic in the amounts used. It will be evident to those of ordinary skill in the art that the optimal dosage of the active ingredient (s) in the pharmaceutical composition will depend on a variety of factors. Relevant factors include, without limitation, the type of animal (e.g., human) , the particular form of the ADCs, the manner of administration, and the composition employed.
- Suitable components may include, for example, antioxidants, fillers, binders, disintegrants, buffers, preservatives, lubricants, flavorings, thickeners, coloring agents, emulsifiers or stabilizers such as sugars and cyclodextrins.
- Suitable antioxidants may include, for example, methionine, ascorbic acid, EDTA, sodium thiosulfate, platinum, catalase, citric acid, cysteine, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxanisol, butylated hydroxytoluene, and/or propyl gallate.
- compositions that comprise the polypeptide complex or the bispecific polypeptide complex disclosed herein and one or more antioxidants such as methionine.
- pharmaceutical acceptable carriers may include, for example, aqueous vehicles such as sodium chloride injection, Ringer’s injection, isotonic dextrose injection, sterile water injection, or dextrose and lactated Ringer’s injection, non-aqueous vehicles such as fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil, or peanut oil, antimicrobial agents at bacteriostatic or fungistatic concentrations, isotonic agents such as sodium chloride or dextrose, buffers such as phosphate or citrate buffers, antioxidants such as sodium bisulfate, local anesthetics such as procaine hydrochloride, suspending and dispersing agents such as sodium carboxymethylcelluose, hydroxypropyl methylcellulose, or polyvinylpyrrolidone, emulsifying agents such as Polysorbate 80 (TWEEN-80) , sequestering or chelating agents such as EDTA (ethylenediaminetetraacetic acid) or EGTA
- Antimicrobial agents utilized as carriers may be added to pharmaceutical compositions in multiple-dose containers that include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride.
- Suitable excipients may include, for example, water, saline, dextrose, glycerol, or ethanol.
- Suitable non-toxic auxiliary substances may include, for example, wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, or agents such as sodium acetate, sorbitan monolaurate, triethanolamine oleate, or cyclodextrin.
- compositions can be a liquid solution, suspension, emulsion, pill, capsule, tablet, sustained release formulation, or powder.
- Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinyl pyrollidone, sodium saccharine, cellulose, magnesium carbonate, etc.
- the pharmaceutical compositions are formulated into an injectable composition.
- the injectable pharmaceutical compositions may be prepared in any conventional form, such as for example liquid solution, suspension, emulsion, or solid forms suitable for generating liquid solution, suspension, or emulsion.
- Preparations for injection may include sterile and/or non-pyretic solutions ready for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use, and sterile and/or non-pyretic emulsions.
- the solutions may be either aqueous or non-aqueous.
- unit-dose parenteral preparations are packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration should be sterile and not pyretic, as is known and practiced in the art.
- a sterile, lyophilized powder is prepared by dissolving the ADCs as disclosed herein in a suitable solvent.
- the solvent may contain an excipient which improves the stability or other pharmacological components of the powder or reconstituted solution, prepared from the powder. Excipients that may be used include, but are not limited to, water, dextrose, sorbital, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agents.
- the solvent may contain a buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, in one embodiment, about neutral pH.
- the resulting solution will be apportioned into vials for lyophilization.
- Each vial can contain a single dosage or multiple dosages of the ADCs provided herein or composition thereof. Overfilling vials with a small amount above that needed for a dose or set of doses (e.g., about 10%) is acceptable so as to facilitate accurate sample withdrawal and accurate dosing.
- the lyophilized powder can be stored under appropriate conditions, such as at about 4 °C to room temperature.
- Reconstitution of a lyophilized powder with water for injection provides a formulation for use in parenteral administration.
- the sterile and/or non-pyretic water or other liquid suitable carrier is added to lyophilized powder. The precise amount depends upon the selected therapy being given and can be empirically determined.
- the antibody-drug conjugates or the pharmaceutical composition may be manufactured into a kit, including an insert which indicates the information for the application, such as the indications, the amount in use, the route to be administrated, and the like.
- the present disclosure relates to the use of the antibody-drug conjugates with improved homogeneity prepared by the process of the first aspect in the manufacture of a pharmaceutical composition or a kit for treating a condition or disorder in a subject.
- the subject may be a mammal, for example, a human.
- the condition or disorder to be treated may be a tumor, cancer, autoimmune disease, or infectious disease.
- the infectious disease may be viral or microbial infection.
- the present disclosure also relates to a method for treating a subject having a condition or disorder, comprising: administrating a therapeutically effective amount of the ADCs with improved homogeneity prepared by the process as disclosed herein or a therapeutically effective amount of the pharmaceutical composition comprising the ADCs with improved homogeneity prepared by the process as disclosed herein to a subject in need thereof, thereby treating or preventing the condition or disorder.
- the subject has been identified as having a condition or disorder likely to respond to the ADCs provided herein.
- the subject may be a mammal, for example, a human.
- the condition or disorder to be treated may be a tumor, cancer, autoimmune disease, or infectious disease.
- the infectious disease may be viral or microbial infection.
- the therapeutically effective amount of the ADCs provided herein will depend on various factors known in the art, such as for example body weight, age, past medical history, present medications, state of health of the subject and potential for cross-reaction, allergies, sensitivities and adverse side-effects, as well as the administration route and extent of disease development. Dosages may be proportionally reduced or increased by one of ordinary skill in the art (e.g., physician or veterinarian) as indicated by these and other circumstances or requirements.
- the ADCs or pharmaceutical composition provided herein may be administered at a therapeutically effective dosage of about 0.01 mg/kg to about 100 mg/kg (e.g., about 0.01 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg) .
- the ADCs or pharmaceutical composition provided herein are administered at a dosage of about 50 mg/kg or less, and in certain of these embodiments the dosage is 10 mg/kg or less, 5 mg/kg or less, 1 mg/kg or less, 0.5 mg/kg or less, or 0.1 mg/kg or less.
- the administration dosage may change over the course of treatment. For example, in certain embodiments the initial administration dosage may be higher than subsequent administration dosages. In certain embodiments, the administration dosage may vary over the course of treatment depending on the reaction of the subject.
- Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic response) .
- a single dose may be administered, or several divided doses may be administered over time.
- the ADCs or pharmaceutical composition provided herein may be administered by any route known in the art, such as for example parenteral (e.g., subcutaneous, intraperitoneal, intravenous, including intravenous infusion, intramuscular, or intradermal injection) or non-parenteral (e.g., oral, intranasal, intraocular, sublingual, rectal, or topical) routes.
- parenteral e.g., subcutaneous, intraperitoneal, intravenous, including intravenous infusion, intramuscular, or intradermal injection
- non-parenteral e.g., oral, intranasal, intraocular, sublingual, rectal, or topical routes.
- condition or disorder treated by the ADCs or pharmaceutical composition provided herein is cancer or a cancerous condition, autoimmune disease or infectious disease.
- the cancer may be antigen positive carcinomas including those of the lung, breast, colon, ovaries, and pancreas, for example, the cancers associated with tumor-associated antigens.
- cancers that can be treated with the ADCs or pharmaceutical composition provided herein include, but are not limited to, solid tumors, including but not limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophogeal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary carcinoma, papillar
- the autoimmune disease may include, but not limited to, Active Chronic Hepatitis, Addison’s Disease, Allergic Alveolitis, Allergic Reaction, Allergic Rhinitis, Alport’s Syndrome, Anaphlaxis, Ankylosing Spondylitis, Anti-phosholipid Syndrome, Arthritis, Ascariasis, Aspergillosis, Atopic Allergy, Atropic Dermatitis, Atropic Rhinitis, Behcet’s Disease, Bird-Fancier’s Lung, Bronchial Asthma, Caplan’s Syndrome, Cardiomyopathy, Celiac Disease, Chagas’ Disease, Chronic Glomerulonephritis, Cogan’s Syndrome, Cold Agglutinin Disease, Congenital Rubella Infection, CREST Syndrome, Crohn’s Disease, Cryoglobulinemia, Cushing’s Syndrome, Dermatomyositi, Discoid Lupus, Dressler’s Syndrome, Eaton-Lambert Syndrome, Echovirus Infection, Encephalomy
- the present disclosure includes a method for treating disease or disorder in a subject, comprising administering to the subject an effective amount of ADCs or pharmaceutical composition provided herein and another therapeutic agent.
- the therapeutic agent is an anti-cancer agent.
- Suitable anticancer agents include, but are not limited to, methotrexate, taxol, L-asparaginase, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, topotecan, nitrogen mustards, cytoxan, etoposide, 5-fluorouracil, BCNU, irinotecan, camptothecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine, paclitaxel, and docetaxel.
- the therapeutic agent is an anti-autoimmune disease agent.
- Suitable anti-autoimmune disease agents include, but are not limited to, cyclosporine, cyclosporine A, mycophenylate mofetil, Sirolimus, tacrolimus, etanercept, prednisone, azathioprine, methotrexate cyclophosphamide, prednisone, aminocaproic acid, chloroquine, hydroxychloroquine, hydrocortisone, dexamethasone, chlorambucil, DHEA, danazol, bromocriptine, meloxicam, and infliximab.
- the therapeutic agent is anti-infectious disease agent.
- the anti-infectious disease agent is, but not limited to, antibacterial agents: [beta] -Lactam Antibiotics: Penicillin G, Penicillin V, Cloxacilliin, Dicloxacillin, Methicillin, Nafcillin, Oxacillin, Ampicillin, Amoxicillin, Bacampicillin, Azlocillin, Carbenicillin, Mezlocillin, Piperacillin, Ticarcillin; Aminoglycosides: Amikacin, Gentamicin, Kanamycin, Neomycin, Netilmicin, Streptomycin, Tobramycin; Macrolides: Azithromycin, Clarithromycin, Erythromycin, Lincomycin, Clindamycin; Tetracyclines: Demeclocycline, Doxycycline, Minocycline, Oxytetracyclinem, Tetracycline; Quinolones: Cinoxacin, Nalidixic Acid; Fluoroquino
- VL, VH genes obtained from the parental antibodies in Table 1 were amplified by PCR from existing plasmid template.
- the TCR C ⁇ and C ⁇ genes (encoding SEQ ID Nos: 2 and 4, except cAb7 and cAb8 which use different C1 and C2 region sequences shown in SEQ ID Nos: 7-9) were synthesized by Genewiz Inc (Suzhou, China) .
- the DNA fragments of VL 1 -C ⁇ and VL 2 -CL were inserted into a linearized vector respectively, which contains a CMV promoter and a human light chain signal peptide.
- the DNA fragments of VH 1 -C ⁇ were inserted into a linearized vector containing human IgG1 constant region CH2-CH3 with “knob” mutations.
- the DNA fragments of VH 2 -CH1 were inserted into a linearized vector containing human IgG1 constant region CH2-CH3 with “hole” mutations.
- the vectors contain a CMV promoter and a human antibody heavy chain signal peptide.
- An exemplary structure of cAb1 is shown in the reaction scheme of Figure 1A.
- Heavy chain and light chain expression plasmids were co-transfected into Expi293 cells (Invitrogen-A14527) using expression system kit (Invitrogen-A14524) according to the manufacturer’s instructions. 5 days after transfection, the supernatants were collected and used for protein purification using protein A chromatography (GE Healthcare-17543802) . If needed, further purifications were conducted using size exclusion chromatography (GE Healthcare-17104301) . Antibody concentration was measured by Nano Drop. The purity of proteins was evaluated by SDS-PAGE and HPLC-SEC.
- the reaction scheme (exemplified by cAb1) shown in Figure 1A was performed. 10 mg/mL mAb in PBS buffer was reduced by 7.5 eq TCEP and the reaction vial was stood at 22 °C for 8 hours. The reduced antibody solution was directly submitted to next step conjugation without TCEP removal.
- the column was previously equilibrated with 5 column volumes of solvent A.
- the ADCs were mixed with 0.67 volume of 5 M NaCl (2.0 M final) and applied to the column. D0 was not retained by the column.
- the different drug loaded species were eluted by sequential step gradients: D2 was eluted with 35%solvent B, D4 was eluted with 70%solvent B, D6 was eluted with 95%solvent B.
- cAb1, cAb3 and cAb4 antibodies obtained ADCs with about 90%or higher homogeneity of D6 species.
- the other 5 antibodies achieve similar results.
- Cysteine was added into the mixture. Then the new mixture was stood at 4 °C for 15 minutes. After 3.0 eq EDTA and 8.0 eq DHAA were added, the mixture was stood at 22 °C for 2 hours.
- cAb1, cAb2, cAb3 and cAb4 antibodies obtained ADCs with more than 80%homogeneity of D2 species.
- the other 4 antibodies achieve similar results.
- the crude product was submitted to a buffer exchange into its storage buffer (1X PBS buffer, pH 7.4, gibco) using spin desalting column (40 kD) .
- the resulting ADCs were submitted to do the characterizations ( Figures 3B-3E) .
Abstract
Provided is a process for preparing highly homogenous antibody-drug conjugates(ADCs) for antibodies. Specifically, in the ADCs prepared by the said process, the content of D2, D4 or D2+D4 can reach more than 90%.
Description
CROSS-REFERENCING
This application claims the benefit of International application PCT/CN2021/117709, filed on September 10, 2021, which is incorporated by reference in its entirety.
The present disclosure relates to a process for preparing antibody-drug conjugates (ADCs) . Specifically, the present disclosure relates to a bio-conjugation process for preparing highly homogenous antibody-drug conjugates (ADCs) for engineered antibodies, specifically, antibodies that are engineered to comprise TCR constant regions in one Fab arm.
The specificity of antibodies for specific antigens on the surface of target cells and molecules has led to their extensive use as carriers of a variety of diagnostic and therapeutic agents. For example, antibodies conjugated to labels and reporter groups such as fluorophores, radioisotopes and enzymes find use in labelling and imaging applications, while conjugation to cytotoxic agents and chemotherapy drugs allows targeted delivery of such agents to specific tissues or structures, for example particular cell types or growth factors, minimizing the impact on normal, healthy tissue and significantly reducing the side effects associated with chemotherapy treatments.
Bispecific antibody (bsAb) refers to a type of antibodies designed to recognize two different epitopes or antigens and aims to treat multifaceted, complex diseases by engaging two disease targets with one molecule. It comes in many formats. WO2019057122 and WO2020057610 disclose examples of WuXiBody
TM platform that enables almost any monoclonal antibody (mAb) sequence pair to be assembled into a bispecific construct and its unique structural flexibility makes the platform convenient to build various formats with different valency. The bispecific antibody generated by the platform also is stable and has no aggregation issue during production.
Antibody-drug conjugates (ADC) are conjugate of an antibody and a drug and have extensive potential therapeutic applications in several disease areas, particularly in cancer, and become a novel targeted drug for disease treatment. ADC contains an antibody for targeting, a connector or linker for drug attachment and a high potent payload (e.g., a drug) as effector. The antibody, by its specificity, directs the drug to its target to release. Since the approvals of Adcetris in 2011 and Kadcyla in 2013 by US FDA, ADC drug development has widely spread for the treatment of cancer. Recently, it has been demonstrated that ADC based on bispecific antibody (e.g. ZW49) can be more efficacious in cancer treatment.
One of the problems facing the conventional conjugation of ADC is the heterogeneity of the ADC molecules where the drug moieties are attached at several sites on the antibody, for example, ranging from 0 to 8 per antibody (Drug-Antibody Ratio, DAR) by cysteine chemistry. ADC molecules of such a mixture not only bring difficulties in analysis and characterization, but also potentially have different pharmacokinetic, distribution, toxicity and efficacy profiles. And non-specific conjugation also frequently results in impaired antibody function.
Strategies are developed to tackle the problem. Genentech’s THIOMAB and Ambrx’s non-natural amino acid incorporation and various enzyme-assisted conjugations all aim to introduce drug moiety in a site-directed fashion and achieve ADC’s homogeneity (narrow DAR distribution) . These methods however are all based on antibody-engineering which may lead to side effects in human. WO2017002776 discloses that by lowing the temperature of the reduction step, DAR4 can be selectively enriched to more than 50%, with most drug on the Fab domain, without altering IgG sequence.
However, there is a continuing need for developing a novel bio-conjugation process which can generate ADCs, including ADCs of bispecific antibodies, with improved homogeneity, and has simple manipulation and reduced cost.
SUMMARY
The present disclosure has an object to develop a novel conjugation process which can generate ADCs with improved homogeneity for a certain type of bispecific antibody, and has simple manipulation and reduced cost. The resultant ADCs have a high content of D2, D6 or D2+4 ADCs, depending on the specific process applied. The ADCs generated by the conjugation process of the disclosure further have optimized safety and efficacy.
The present disclosure relates to a combination of metal ion chelating technology and a certain type of bispecific antibody, the WuXiBody, for developing new conjugation processes. Compared with conventional conjugation process, the homogeneity of antibody-drug conjugate (ADC) products generated from the conjugation process of the present disclosure can be dramatically improved. Moreover, ADC products site-specifically conjugated with two different drug moieties can be obtained.
In one aspect, the disclosure provides a process for preparing an antibody-drug conjugate (ADC) , wherein the antibody comprises a pair of T cell receptor (TCR) constant regions instead of CH1 and CL domains in at least one arm, and the pair of TCR constant regions is capable of forming a non-native interchain disulfide bond (s) , and wherein the process comprises the following steps:
(a) incubating a reductant and the antibody in a buffer system;
(b) introducing an excess amount of a linker-drug moiety to react with reduced thiol groups resulted from step (a) ; and
(c) recovering the resultant antibody-drug conjugate.
Optionally, the process further comprises adding an effective amount of oxidant to re-oxidize the unreacted thiol groups after step (b) and before recovering the resultant antibody-drug conjugate.
The inventors have surprisingly found that due to steric hindrance, the non-native interchain disulfide bond (s) between the pair of TCR constant regions is/are not accessible to reductants and thus cannot be reduced for drug conjugation.
In some embodiments, the antibody as described herein comprises a first and a second antigen-binding moiety, wherein the first antigen-binding moiety comprises: a first heavy chain variable domain (VH) operably linked to a T cell receptor (TCR) constant region (C1) , and a first light chain variable domain (VL) operably linked to a second TCR constant region (C2) , wherein C1 and C2 are capable of forming a non-native interchain disulfide bond, and
the second antigen-binding moiety is in Fab, scFv or VHH format.
In some embodiments, the second antigen-binding moiety is in Fab format and comprises: a second VH operably linked to an antibody heavy chain CH1 domain, and a second VL operably linked to an antibody light chain constant (CL) domain. In some other embodiments, the second antigen-binding moiety is in scFv format and comprises: a second VH operably linked to a second VL. In some other embodiments, the second antigen-binding moiety is in VHH format and comprises a single variable domain.
In some embodiments, the antibody is a bispecific antibody with the first and second antigen-binding moieties targeting different antigens or epitopes. In some other embodiments, the antibody is a mono-specific antibody with the first and second antigen-binding moieties targeting the same epitope.
In some embodiments, the C1 region and C2 regions of the antibody as disclosed herein comprises an engineered T cell receptor (TCR) constant regions. Specifically, the C1 region may comprise the amino acid sequence of SEQ ID No: 2, 7 or a variant thereof with at least 90%identity; and the C2 region may comprise the amino acid sequence of SEQ ID No: 4, 8, 9 or a variant thereof with at least 90%identity. The C1 and C2 regions are capable of forming a dimer, and the non-native interchain disulfide bond (s) is/are capable of stabilizing the dimer. In some embodiments, amino acid C58 in SEQ ID No: 2 and amino acid C49 in SEQ ID No: 4 are capable of forming a non-native interchain disulfide bond.
In some embodiments, the antibody comprises an IgG Fc region, such as an IgG1, IgG2, IgG3 or IgG4 isotype.
In some embodiments, the Fc region further comprises a knob into hole structure. Specifically, the sequence of the hinge region and the Fc region in one chain ( “knob” chain) is as shown in SEQ ID No: 5, and the sequence of the hinge region and the Fc region in the other chain ( “hole” chain) is as shown in SEQ ID No: 6.
In some embodiments, from N terminus to C terminus, the antibody comprises the following structure (E17) : in the 1
st heavy chain, VH1-C1-hinge-Fc; in the 2
nd heavy chain, VH2-CH1-hinge-Fc; in the 1
st light chain, VL1-C2; and in the 2
nd light chain, VL2-CL, wherein VH1 and VL1 refer to the first VH and VL and VH2 and VL2 refer to the second VH and VL, respectively. “-” represents an operable linkage, generally via a peptide linker.
In some other embodiments, from N terminus to C terminus, the antibody comprises the following structure: in the 1
st heavy chain, VH1-C1-hinge-Fc-scFv; in the 2
nd heavy chain, VH1- CH1-hinge-Fc-scFv; in the 1
st light chain, VL1-C2; and in the 2
nd light chain, VL1-CL. The scFv constitutes the second antigen-binding moiety and can also be replaced by a VHH format.
In some embodiments, to obtain a high content of D2 ADCs, the incubation in step (a) is performed in the presence of an effective amount of a metal ion (s) such as a divalent metal ion (s) and a transition metal ion (s) . The resultant antibody-drug conjugate comprises D2 in a content higher than 80 wt%, for example, higher than 85 wt%, higher than 90 wt%, or higher than 95 wt %, on the basis of total weight of D0 and D2.
In some embodiments, the incubation in step (a) is performed in the presence of an effective amount of metal ions such as a divalent metal ion or a transition metal ion and the process further comprises between steps (b) and (c) : removing the transition metal ions or divalent metal ions from the product of step (b) , then introducing a reductant again and incubating with an excess amount of a different linker-drug moiety. The resultant antibody-drug conjugate comprises D2+4 in a content higher than 65 wt%, for example, higher than 70 wt%, higher than 80 wt%, or higher than 90 wt%, on the basis of total weight of ADCs.
In some embodiments, to obtain a high content of D6 ADCs, the incubation in step (a) is not performed in the presence of an effective amount of transition metal ions or divalent metal ions. The resultant antibody-drug conjugate comprises D6 in a content higher than 85 wt%, for example, higher than 90 wt%, higher than 91 wt%, higher than 92 wt%, or higher than 93 wt%, on the basis of total weight of D0, D2, D4, and D6.
In one aspect, the present disclosure provides a process for preparing an antibody-drug conjugate (ADC) , wherein the antibody comprises a first and second antigen-binding moiety,
the first antigen-binding moiety comprises: a first heavy chain variable domain (VH) operably linked to a T cell receptor (TCR) constant region (C1) , and a first light chain variable domain (VL) operably linked to a second TCR constant region (C2) , and
the second antigen-binding moiety comprises: a second VH operably linked to an antibody heavy chain CH1 domain, and a second VL operably linked to an antibody light chain constant (CL) domain,
and wherein the process comprises the following steps:
(a) incubating a reductant and the bispecific antibody in the presence of an effective amount of transition metal ions or divalent metal ions in a buffer system to selectively reduce inter-chain disulfide bonds within the antibody;
(b) introducing an excess amount of a first linker-drug moiety to react with reduced thiol groups resulted from step (a) ;
(c) removing the transition metal ions or divalent metal ions from the product of step (b) ;
(d) introducing a reductant again and incubating with an excess amount of a second linker-drug moiety; and
(e) recovering the resultant antibody-drug conjugate.
Optionally, the process further comprises adding an effective amount of oxidant to re-oxidize the unreacted thiol groups after step (d) .
In some embodiments, the reductants added in step (a) and (d) are different, such as one is TCEP and the other is TDD. In some other embodiments, the reductants added in step (a) and (d) are the same, e.g. both are TCEP.
In some embodiments, the resultant antibody-drug conjugate comprises D2+4 in a content higher than 65 wt%, for example, higher than 70 wt%, higher than 80 wt%, or higher than 90 wt%, on the basis of total weight of ADCs.
In some embodiments, the first drug is MMAF and the second drug is DXD.
In some embodiments, the metal ions in step (a) are selected from a group of divalent ions and transition metal ions comprising Zn2+, Cd2+, Hg2+, Ca2+, Mg2+, or any combination thereof. For example, the metal ion in step (a) is Zn2+. The transition metal ion which is suitable to be used in the conjugation processes of the present disclosure may include, but not limited to, Zn
2+, Cd
2+, Hg
2+, and the like. Among others, Zn
2+, Ca
2+ and Mg
2+ may be used due to their easily availability and low cost. For example, suitable transition metal salts or divalent metal ions may be added in step (a) as long as they are soluble in the reaction solution so that free transition metal ions can be released in the reaction solution. In this regard, ZnCl
2, Zn (NO
3)
2, ZnSO
4, Zn (CH
3COO)
2, ZnI
2, ZnBr
2, Zinc Formate, and zinc tetrafluoroborate may be mentioned as suitable zinc salts. Similarly, CaCl
2, Ca (NO
3)
2, CaSO
4, MgCl
2, Mg (NO
3)
2, and MgSO
4 can be applied. Likewise, other transition metal salts which are soluble and can release free Cd
2+, or Hg
2+ ions in the reaction solution can be mentioned, which include, but not limited to, CdCl
2, Cd (NO
3)
2, CdSO
4, Cd (CH
3COO)
2, CdI
2, CdBr
2, cadmium formate, and cadmium tetrafluoroborate; HgCl
2, Hg (NO
3)
2, HgSO
4, Hg (CH
3COO)
2, HgBr
2, Mercury (II) formate, and Mercury (II) tetrafluoroborate; and the like.
In some embodiments, the buffer system used in step (a) is selected from a group comprising Hepes, Histidine buffer, PBS, and MES, and the pH value is about 5.5 to 8.
In some embodiments, the antibody to be conjugated is added in step (a) to be a final concentration of about 0.01 to 0.1 mM.
In some embodiments, step (a) is performed at a temperature of about -10℃ to 37℃, for example, at about 0℃ to 20℃.
In some embodiments, the reductant in step (a) is TCEP.
In some embodiments, the oxidant is DHAA.
In some embodiments, the linker-drug moiety is maleimide bearing a drug, an organic bromide bearing a drug, or an organic iodide bearing a drug.
In some embodiments, the variable regions of the first and second antigen binding moiety are derived from antibodies which are already known, on the market, or developed de novo, such as any of the following antibodies: trastuzumab, pertuzumab, sacituzumab, abciximab, adalimumab, alefacept, alemtuzumab, basiliximab, belimumab, bezlotoxumab, canakinumab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, golimumab, inflectra, ipilimumab, ixekizumab, natalizumab, nivolumab, olaratumab, omalizumab, palivizumab, panitumumab, pembrolizumab, rituximab, tocilizumab, trastuzumab, secukinumab, and ustekinumab. Preferably, the variable regions (or at least the CDR regions) of the first and second antigen binding moieties are same as those of the antibodies which are already known or developed de novo.
In some embodiments, the first VH and the first VL are from Trastuzumab and the second VH and the second VL are from pertuzumab, or vice versa. In some other embodiments, the first VH and the first VL are from Trastuzumab and the second VH and the second VL are from sacituzumab, or vice versa.
In some embodiments, the drug to be conjugated is selected from a group comprising diagnostic agents, therapeutic agents and labelling agents.
In some embodiments, the metal ions will be removed in purification step by using EDTA as chelating reagent, which will be filtered out in subsequent dialysis, ultrafiltration or gel filtration.
In one aspect, the present disclosure provides the antibody-drug conjugates prepared by the process of any one of disclosed processes.
In one aspect, the present disclosure provides a pharmaceutical composition comprising an effective amount of the antibody-drug conjugate as disclosed herein and a pharmaceutically acceptable carrier or vehicle.
In one aspect, the present disclosure provides use of the antibody-drug conjugates as disclosed herein in the manufacture of a pharmaceutical composition or a kit for treating a condition or disorder in a subject.
In one aspect, the present disclosure provides a method for treating a condition or disorder in a subject, comprising a step of administrating to the subject a therapeutically effective amount of the antibody-drug conjugate or the pharmaceutical composition as disclosed herein.
In some embodiments, the condition or disorder is a tumor, cancer, autoimmune disease, or infectious disease. For example, the cancer is breast cancer. The subject may be a mammal, for example, a human.
The foregoing and other features and advantages of the disclosure will become more apparent from the following detailed description of several embodiments which proceeds with reference to the accompanying figures.
DESCRIPTION OF DRAWINGS
Figure 1. Reaction scheme according to some embodiments wherein three pairs of interchain disulfide bonds of the bispecific antibody cAb1 (Trastuzumab x Pertuzumab) are reduced and site-specifically conjugated with MC-MMAF (Fig. 1A) ; HIC profile of cAb1 conjugation which shows DAR6 abundance (Fig. 1B) ; and Mass Spectrometry profile of cAb1 conjugation (Fig. 1C) . Figure 1D is the HIC profile of two other bispecific antibodies cAb3 and cAb4 which are similarly conjugated.
Figure 2. Reaction scheme according to some embodiments wherein Zn
2+ is added and only one pair of interchain disulfide bonds of the bispecific antibody is reduced and site-specifically conjugated with MC-MMAF (Fig. 2A) ; HIC profile of four bispecific antibodies cAb1, cAb2, cAb3 and cAb4 (Fig. 2B) conjugated as described in (Fig. 2A) .
Figure 3. Reaction scheme according to some embodiments wherein the bispecific antibody cAb1 is conjugated in two steps with two different drugs (e.g. MMAF and DXD) , respectively (Fig. 3A) ; MS profiles of resultant cAb1 ADC (Fig. 3B) , cAb2 ADC (Fig. 3C) , cAb3 ADC (Fig. 3D) and cAb4 ADC (Fig. 3E) .
While the present disclosure may be embodied in many different forms, disclosed herein are specific illustrative embodiments thereof that exemplify the principles of the disclosure. It should be emphasized that the present disclosure is not limited to the specific embodiments illustrated. Moreover, any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
Generally, nomenclature used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Abbas et al., Cellular and Molecular Immunology, 6th ed., W. B. Saunders Company (2010) ; Sambrook J. &Russell D. Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (2000) ; Ausubel et al., Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Wiley, John &Sons, Inc. (2002) ; Harlow and Lane Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (1998) ; and Coligan et al., Short Protocols in Protein Science, Wiley, John &Sons, Inc. (2003) . The nomenclature used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. All publications mentioned in this specification are herein incorporated by reference in their entirety.
DEFINITIONS
In order to better understand the disclosure, the definitions and explanations of the relevant terms are provided as follows.
Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. More specifically, as used in this specification and the appended claims, the singular forms “a, ” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an antibody” includes a plurality of antibodies; reference to “a transition metal ion” includes mixtures of transition metal ions, and the like. In this application, the use of “or” means “and/or” unless stated otherwise.
Throughout this disclosure, unless the context requires otherwise, the words “comprise” , “comprises” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements. By “consisting of” is meant including, and limited to, whatever follows the phrase “consisting of” . Thus, the phrase “consisting of” indicates that the listed elements are required or mandatory, and that no other elements may be present. By “consisting essentially of” is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of” indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.
As used herein, the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 30, 25, 20, 25, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1%to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length. In particular embodiments, the terms “about” or “approximately” when preceding a numerical value indicates the value plus or minus a range of 15%, 10%, 5%, or 1%.
“Antibody-drug conjugate” or ADC refers to a conjugate formed by covalently coupling a drug to an antibody directly or indirectly via one or more suitable linkers. ADC is generally in a format of antibody-linker-drug conjugate. The Antibody-drug conjugates combine ideal properties of both antibodies and cytotoxic drugs (or those of other properties) by targeting potent cytotoxic (or other) drugs to the antigen-expressing tumor cells (or other cells/organs) , thereby enhancing their anti-tumor (or other medicinal) activity. ADCs are designed with the intention to discriminate between healthy cells and diseased tissue such as tumor cells in a tumor.
The term “drug” or “payload” as used herein refers to any cytotoxic molecule which has for example, an antitumor effect, anti-infection or anti-inflammation effect, and has at least one substituted group or a partial structure allowing connection to a linker structure. The drug may kill cells (e.g. cancer cells) and/or inhibit growth, proliferation, or metastasis of cells (e.g. cancer cells) , thereby reducing, alleviating, or eliminating one or more symptoms of a disease or disorder (e.g. cancer) .
The term “linker” as used herein refers to a reactive molecule which contains at least two reactive groups, one of which can covalently bond a drug molecule and the other of which can covalently couple to an antibody.
The term “antibody” as used herein encompasses any immunoglobulin, monoclonal antibody, polyclonal antibody, multi-specific antibody, bispecific antibody, multivalent or bivalent antibody that binds to a specific antigen. A native intact antibody comprises two heavy chains and two light chains. Each heavy chain consists of a variable region ( “HCVR” ) and a first, second, and third constant region (CH1, CH2 and CH3) , while each light chain consists of a variable region (“LCVR” ) and a constant region (CL) . Mammalian heavy chains are classified as α, δ, ε, γ, and μ, and mammalian light chains are classified as λ or κ. The antibody generally has a “Y” shape, with the stem of the Y consisting of the second and third constant regions of two heavy chains bound together via disulfide bonding. Each arm of the Y includes the variable region and first constant region of a single heavy chain bound to the variable and constant regions of a single light chain. The variable regions of the light and heavy chains are responsible for antigen binding. The variable regions in both chains generally contain three highly variable loops called the complementarity determining regions (CDRs) (light (L) chain CDRs including LCDR1, LCDR2, and LCDR3, heavy (H) chain CDRs including HCDR1, HCDR2, HCDR3) . CDR boundaries for antibodies may be defined or identified by the conventions of Kabat, Chothia, or Al-Lazikani (Al-Lazikani, B., Chothia, C., Lesk, A.M., J. Mol. Biol., 273 (4) , 927 (1997) ; Chothia, C. et al., J Mol Biol. Dec 5; 186 (3) : 651-63 (1985) ; Chothia, C. and Lesk, A.M., J. Mol. Biol., 196, 901 (1987) ; Chothia, C. et al., Nature. Dec 21-28; 342 (6252) : 877-83 (1989) ; Kabat E.A. et al., National Institutes of Health, Bethesda, Md. (1991) ) , among others. The three CDRs are interposed between flanking stretches known as framework regions (FRs) , which are more highly conserved than the CDRs and form a scaffold to support the hypervariable loops. Each HCVR and LCVR comprises four FRs, and the CDRs and FRs are arranged from amino terminus to carboxy terminus in the order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The constant regions of the heavy and light chains are not involved in antigen binding, but exhibit various effector functions. Antibodies are assigned to classes based on the amino acid sequence of the constant region of their heavy chain. The five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, which are characterized by the presence of α, δ, ε, γ, and μ heavy chains, respectively. Several of the major antibody classes are divided into subclasses such as IgG1 (γ1 heavy chain) , IgG2 (γ2 heavy chain) , IgG3 (γ3 heavy chain) , IgG4 (γ4 heavy chain) , IgA1 (α1 heavy chain) , or IgA2 (α2 heavy chain) .
The term “antibody fragment” comprise a portion of a full-length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab’, F (ab’) 2, and Fv fragments; diabodies; linear antibodies; minibodies (Olafsen et al. (2004) Protein Eng. Design &Sel. 17 (4) : 315-323) , fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDR (complementary determining region) , and epitope -binding fragments of any described herein which immunospecifically bind to cancer cell antigens, viral antigens or microbial antigens, single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
The term “antigen-binding moiety” as used herein refers to an antibody fragment formed from a portion of an antibody comprising one or more CDRs, or any other antibody fragment that binds to an antigen but does not comprise an intact native antibody structure. Examples of antigen-binding moiety include, without limitation, a variable domain, a variable region, a diabody, a Fab, a Fab’, a F (ab’) 2, an Fv fragment, a scFv, a disulfide stabilized Fv fragment (dsFv) , a (dsFv) 2, a bispecific dsFv (dsFv-dsFv’) , a disulfide stabilized diabody (ds diabody) , a multispecific antibody, a camelized single domain antibody, a nanobody, a domain antibody, and a bivalent domain antibody. An antigen-binding moiety is capable of binding to the same antigen to which the parent antibody binds. In certain embodiments, an antigen-binding moiety may comprise one or more CDRs from a particular human antibody grafted to a framework region from one or more different human antibodies. For more and detailed formats of antigen-binding moiety are described in Spiess et al, 2015 (Supra) , and Brinkman et al., mAbs, 9 (2) , pp. 182–212 (2017) , which are incorporated herein by their entirety.
“Fab” with regard to an antibody refers to that portion of the antibody consisting of a single light chain (both variable and constant regions) associating to the variable region and first constant region of a single heavy chain by a disulfide bond. In certain embodiments, both the first and second antigen-binding moieties of the antibody to be conjugated are in Fab format. Further, the constant regions (i.e. CH1 and CL) of both chains of the Fab are replaced with engineered or modified TCR constant regions.
“Fc” with regard to an antibody refers to that portion of the antibody comprising the second (CH2) and third (CH3) constant regions of a first heavy chain bound to the second and third constant regions of a second heavy chain via disulfide bonding, and optionally a hinge region. The Fc portion of the antibody is responsible for various effector functions such as ADCC, and CDC, but does not function in antigen binding.
“Hinge region” in terms of an antibody includes the portion of a heavy chain molecule that joins the CH1 domain to the CH2 domain. This hinge region comprises approximately 25 amino acid residues and is flexible, thus allowing the two N-terminus antigen binding regions to move independently.
The term “knob into hole” , as used herein, refers to engineering the CH3 domain of antibody Fc region to create either a “knob” or a “hole” in each heavy chain to promote heterodimerization. Generally, a “knob” is created by replacing T366 with a bulky residue W on one heavy chain, and the corresponding “hole” is made by triple mutations of T366S, L368A and Y407V on the other heavy chain. The knob-into-hole structure may comprise other substitutions, as familiar in the art. The “EU numbering system” or “EU index” is generally used when referring to a residue in an immunoglobulin heavy chain constant region (e.g., the EU index reported in Kabat et al. Sequences of Proteins of Immunological Interest (5th Ed. ) , US Dept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242) . Unless stated otherwise herein, references to residue numbers in the constant domain of Fc regions means residue numbering by the EU numbering system. In some embodiments, the sequence of the hinge region and the Fc region in one chain ( “knob” chain) is as shown in SEQ ID No: 5, and the sequence of the hinge region and the Fc region in the other chain ( “hole” chain) is as shown in SEQ ID No: 6.
The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes) , each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al. (1975) Nature 256: 495, or may be made by recombinant DNA methods (see for example: US 4816567; US 5807715) . The monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in e.g. Clackson et al. (1991) Nature, 352: 624-628; Marks et al. (1991) J. Mol. Biol., 222: 581-597.
A “WuXiBody” as used herein refers to a bispecific antibody comprising a soluble chimeric protein with the variable domains of an antibody and the constant domains of a TCR (e.g. in the first antigen-binding moiety) , wherein the subunits (such as alpha and beta domains) of the TCR constant domains are linked by one or more engineered disulfide bonds. The WuXiBody also encompasses WuXiBody 2.0 antibodies which comprise a numerous variety of modified TCR constant domain sequences (see WO2022/156687) . The TCR constant domains may be engineered to form more than one pair of disulfide bonds to improve stability and/or expression level. In one type of the WuXiBody, the antibody comprises a first antigen-binding moiety in one arm and a second antigen-binding moiety in the other arm, both in Fab format and operably linked to one chain of the immunoglobulin Fc region at the C terminus. In a different WuXiBody form, the first antigen-binding moiety and the second antigen-binding moiety is intervened by the Fc region. Specifically, the antibody may comprise a first antigen-binding moiety at one terminal of the Fc region which is a Fab, and a second antigen-binding moiety at the other terminal of the Fc region which is a Fab, scFv or VHH. Alternatively, the antibody in WuXiBody form comprises a first antigen-binding moiety operably linked to the second antigen-binding moiety, which is further operably linked to the Fc region. A detailed description of various formats of WuXiBody can be found in WO2019057122, WO2019057124 and WO2020057610 (all of which incorporated herein by reference in its entirety) .
A native “T cell receptor” or a native “TCR” is a heterodimeric T cell surface protein which is associated with invariant CD3 chains to form a complex capable of mediating signal transduction. TCR belongs to the immunoglobulin superfamily, and is similar to a half antibody with a single heavy chain and a single light chain. a native TCR has an extracellular portion, a transmembrane portion, and an intracellular portion. The extracellular domain of a TCR has a membrane-proximal constant region and a membrane-distal variable region.
The terms “Trastuzumab x Pertuzumab” , “Pertuzumab x Trastuzumab” , “Trastuzumab x Sacituzumab” and “Sacituzumab x Trastuzumab” and similar designations, as used herein, are named following the same principle, i.e. refer to bispecific antibodies (preferably WuXiBody BsAbs) that comprise a first antigen binding moiety derived from the first antibody, and a second antigen-binding moiety derived from the second antibody. By “derived from” it is meant that the variable regions are same as those in the parent antibody or have at least 80%homology (e.g. at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) yet still retain the binding ability to the targeted antigen. For example, the variable regions from parental antibodies may be humanized, affinity matured, or glycosylation modified before being constructed into the antibody format as disclosed herein. The methods for modification of the variable regions, including CDRs and framework regions, are familiar to a person in the art.
The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes) , e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
An “isolated antibody” is one which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95%or 99%purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF) , capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) . For review of methods for assessment of antibody purity, see, e.g., Flatman et al, J. Chromatogr. B 848: 79-87 (2007) .
A “disulfide bond” refers to a covalent bond with the structure R-S-S-R’. The amino acid cysteine comprises a thiol group that can form a disulfide bond with a second thiol group, for example from another cysteine residue. The disulfide bond can be formed between the thiol groups of two cysteine residues residing respectively on the two polypeptide chains, thereby forming an interchain bridge or interchain bond.
The term “transition metal” , as used herein, refers to the elements of groups 4-12, justified by their typical chemistry, i.e. a large range of complex ions in various oxidation states, colored complexes, and catalytic properties either as the element or as ions (or both) . Sc and Y in Group 3 are also generally recognized as transition metals.
The term “effective amount” used herein in relation to the metal ions (including transition metal ions and divalent metal ions) , refer to an amount of the metal ions that is sufficient to chelate with the disulfide bonds in the hinge region of the antibody and thus protect the disulfide bonds from reduction. The “effective amount” may be considered in the context of utilizing one or more metal ions, and a single metal ion may be considered as given in an effective amount if, in conjunction with one or more other metal ions, the desirable result is achieved. The effective amount of the metal ions can be empirically determined by a person skilled in the art based on the specific compositions and conditions used for conjugation. In some embodiments, the effective amount of metal ions in the reaction solution in step (a) is about 0.01 mM to 0.2 mM.
The term “DAR” or “Drug-to-Antibody Ratio” , as used herein, refers to the average number of drugs conjugated to an antibody, which is an important attribute of ADCs. The DAR value affects the efficacy of the drug, as low drug loading reduces the potency, while high drug loading can negatively affect pharmacokinetics (PK) and toxicity. Various analytical methods can be used to measure DAR, such as Ultraviolet-Visible (UV/Vis) spectroscopy, Hydrophobic interaction chromatography (HIC) , Reversed phase high-performance liquid chromatography (RP-HPLC) and Liquid chromatography coupled with electrospray ionization mass spectrometry (LC-ESI-MS) . Hydrophobic interaction chromatography (HIC) is a leading technique for the characterization of DAR values and drug loading distribution. The conjugated species are separated based on an increased hydrophobicity caused by the increased drug-load. In terms of cysteine-conjugated ADCs, the unconjugated antibody with the least hydrophobicity is eluted first while the most hydrophobic, most drug conjugated form elutes last, generating a quantitative elution profile. The area percentage of a peak represents the relative amount of each drug-loaded ADC species. The payload distribution is derived from the HIC profile while the average DAR is also calculated from the percentage peak area. As demonstrated herein, the ADCs conjugated by the process as disclosed herein are highly homogeneous. The content of DAR2, DAR6 or DAR2+4 (i.e. D2, D6, or D2+4) , depending on the specific processes used, can reach at least 80 wt%of total ADCs. DAR2+4 (D2+4) refers to a bi-drug ADC that comprises two molecules of the first drug and four molecules of the second drug per antibody.
As is known in the art, a mixture of antibody-drug conjugates will be generated by the conventional conjugation processes. In general, one antibody molecule belonging to IgG1 or IgG4 subclass has 4 inter-chain S-Sbonds, each of which is formed with two -SH groups. The antibody molecule can be subjected to partial or complete reduction of one or more interchain S-Sbonds to form 2n (n is an integer selected from 1, 2, 3 or 4) reactive -SH groups, and thus, the number of drugs coupling to a single antibody molecule is 2, 4, 6 or 8. In accordance with the number of drugs coupling to a single antibody molecule, the different conjugates containing different number of drug molecules are denominated as D0, D2, D4, D6 and D8.
If the number of drugs coupling to a single antibody molecule is 0, the product is referred to as D0. Accordingly, D2 refers to the ADC in which two drug molecules are coupled to one single antibody molecule, where two drug molecules may be coupled to -SH groups generated by reduction of S-Sbonds between heavy and light chains via linkers, or may be coupled to -SH groups generated by reduction of S-Sbonds between heavy and heavy chains via linkers. D4 refers to the ADC in which four drug molecules are coupled to one single antibody molecule, where four drug molecules may be coupled to four -SH groups generated by reduction of two S-Sbonds between heavy and light chains, or between heavy and heavy chains via linkers, or two drug molecules may be coupled to two -SH groups generated by reduction of one S-Sbond between heavy and light chains via linkers and the other two drug molecules may be coupled to two -SH groups generated by reduction of one S-Sbond between heavy and heavy chains vis linkers. D6 refers to the ADC in which six drug molecules are coupled to one single antibody molecule, where four drug molecules may be coupled to four -SH groups generated by reduction of two S-Sbonds between heavy and light chains via linkers and two drug molecules may be coupled to two -SH groups generated by reduction of one S-Sbonds between heavy and heavy chains via linkers, or four drug molecules may be coupled to four -SH groups generated by reduction of two S-Sbonds between heavy and heavy chains via linkers and two drug molecules may be coupled to two -SH groups generated by reduction of one S-Sbonds between heavy and light chains via linkers. And D8 refers to the ADC in which eight drug molecules are coupled to one single antibody molecule, i.e., all the four S-Sbonds in one antibody molecule are reduced to eight -SH groups and each -SH group attaches one drug molecule. In general, the heterogeneous mixture of ADC molecules generated by conventional conjugation processes or the bio-conjugation process of the present disclosure is a mixture of D0, D2, D4, D6 and D8.
And thus, the term “homogeneity” of antibody-drug conjugates is used to describe the property of dominance of one specific type of antibody-drug conjugate (preferably, one type selected from D2, D4, D6 conjugates) in one given mixture of antibody-drug conjugates. In the present disclosure, the “homogeneity” of antibody-drug conjugates refers to a high level of one specific type of ADC in the mixture of antibody-drug conjugates.
The term “pharmaceutically acceptable” indicates that the designated carrier, vehicle, diluent, excipient (s) , and/or salt is generally chemically and/or physically compatible with the other ingredients comprising the formulation, and physiologically compatible with the recipient thereof.
A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is bioactivity acceptable and nontoxic to a subject. Pharmaceutical acceptable carriers for use in the pharmaceutical compositions disclosed herein may include, for example, pharmaceutically acceptable liquid, gel, or solid carriers, aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, anesthetics, suspending/dispending agents, sequestering or chelating agents, diluents, adjuvants, excipients, or non-toxic auxiliary substances, other components known in the art, or various combinations thereof.
The term “subject” includes any human or nonhuman animal, for example, humans.
The term “cancer” , as used herein, refers to any tumor or a malignant cell growth, proliferation or metastasis-mediated, solid tumors and non-solid tumors such as leukemia and initiate a medical condition. A “tumor” comprises one or more cancerous cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastema, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer) , lung cancer including small-cell lung cancer, non-small cell lung cancer ( “NSCLC” ) , adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.
The term “treatment” , “treating” or “treated” , as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human or an animal, in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, regression of the condition, amelioration of the condition, and cure of the condition. Treatment as a prophylactic measure (i.e., prophylaxis, prevention) is also included. For cancer, “treating” may refer to dampen or slow the tumor or malignant cell growth, proliferation, or metastasis, or some combination thereof. For tumors, “treatment” includes removal of all or part of the tumor, inhibiting or slowing tumor growth and metastasis, preventing or delaying the development of a tumor, or some combination thereof.
ADC Preparation in General
Antibody-drug conjugates are usually produced by two conventional chemical strategies, Lysine based conjugation and Cysteine from the reduction of interchain sulfide bonds based conjugation. For conjugation based on Cysteine from the reduction of interchain sulfide bonds, it comprises a step of opening inter-chain disulfide bonds in the presence of various reductants, such as TCEP, DTT and so on, followed by nucleophilic reaction of thiol groups. In this conjugation process, antibody-drug conjugates are typically formed by conjugating one or more antibody cysteine thiol groups to one or more linker moieties bound to a drug thereby forming an antibody-linker-drug complex. Since free cysteine thiol (RSH, sulfhydryl) groups are relatively reactive, proteins with cysteine residues often exist in their oxidized form as disulfide-linked oligomers or have internally bridged disulfide groups. Disulfide dimer formation renders the Cys unreactive for conjugation to a drug, ligand, or other label.
The number of drugs coupling to a single antibody molecule is an important factor for the efficacy and safety of the resultant ADC. For example, in the conjugation process based on native inter-chain disulfide bond reduction, the inter-chain S-Sbonds are more accessible to solvents than other disulfide bonds. Therefore, the inter-chain disulfide bonds can be used as the binding sites for coupling a drug (or a drug-linker) to an antibody. In general, one therapeutic antibody molecule belonging to IgG1 or IgG4 subclass has 4 inter-chain S-Sbonds, each of which is formed with two -SH groups, and thus, the number of drugs coupling to a single antibody molecule is 2, 4, 6 or 8. If the number of drugs coupling to a single antibody molecule is 0, the product is referred to as D0. Accordingly, D2 refers to the ADC in which two drug molecules are coupled to one single antibody molecule. D4 refers to the ADC in which four drug molecules are coupled to one single antibody molecule. D6 refers to the ADC in which six drug molecules are coupled to one single antibody molecule. And D8 refers to the ADC in which eight drug molecules are coupled to one single antibody molecule, i.e., all the four S-Sbonds in one antibody molecule are reduced to eight -SH groups and each -SH group attaches one drug molecule. In general, the heterogeneous mixture of ADC molecules generated by conventional conjugation processes is a mixture of D0, D2, D4, D6 and D8.
It is well known in the art that heterogeneous ADC products are generally of lower efficacy and unsatisfactory PK properties. Among them, D0 has no ADC efficacy, and due to their hydrophobicity induced from payload (i.e., drug) molecules, D8 is considered to be the reason of instability in the circulation. Although antibody-drug conjugate potency in vitro has been shown to be directly dependent on drug loading (Hamblett KJ, et al., Clin Cancer Res. 2004 Oct 15; 10 (20) : 7063-70) , in-vivo antitumor activity of antibody-drug conjugates with four drugs per molecule (D4) was comparable with conjugates with eight drugs per molecule (D8) at equal mAb doses, even though the conjugates contained half the amount of drugs per mAb.
Drug-loading also affected plasma clearance, with D8 conjugate being cleared 3-fold faster than D4 conjugate and 5-fold faster than a D2 conjugate. Antibody-drug conjugates with improved homogeneity provide benefits in therapy, for example a higher therapeutic index, improving efficacy and reducing toxicity of the drug. Homogeneous antibody conjugates also provide more accurate and consistent measurements in diagnostic and imaging applications.
Conventionally, the drug-loading of an ADC may be controlled in different ways, e.g., by: (i) limiting the molar excess of drug-linker intermediate or linker reagent relative to antibody, (ii) limiting the conjugation reaction time or temperature, (iii) partial or limiting reductive conditions for cysteine thiol modification, (iv) engineering by recombinant techniques the amino acid sequence of the antibody such that the number and position of cysteine residues is modified for control of the number and/or position of linker-drug attachments (such as thioMab or thioFab and those disclosed in WO2006/034488, herein incorporated by reference in its entirety) .
In one aspect, the present disclosure provides a method or process for preparing highly homogeneous ADCs for antibodies. The antibodies comprise an engineered Fab whose CH1 and CL domains are replaced by a pair of T cell receptor (TCR) constant regions, and the pair of TCR constant regions is capable of forming a non-native interchain disulfide bond. This disulfide bond is capable of stabilizing the dimer formed between the pair of TCR constant regions, and as described above, is less accessible to solvents or reductants than native disulfide bonds.
In some embodiments, the antibodies to be conjugated herein are constructed via
Platform and also named as “WuXiBody” . A “WuXiBody” is generally a bispecific (or multispecific) antibody that comprises a first and second antigen-binding moiety, the first antigen-binding moiety is an engineered Fab comprising a first heavy chain variable domain (VH) operably linked to a first T cell receptor (TCR) constant region (C1) , and a first light chain variable domain (VL) operably linked to a second TCR constant region (C2) , while the second antigen-binding moiety may be in Fab, scFv, VHH format, among others. In certain embodiments, the second antigen-binding moiety is also in Fab format and comprises a second VH operably linked to an antibody heavy chain CH1 domain, and a second VL operably linked to an antibody light chain constant (CL) domain. In other words, in the first antigen-binding moiety, the commonly present CH1 domain and CL domain are replaced by a pair of TCR constant regions, thus the native disulfide bond between CH1 domain and CL domain is also replaced by one or more engineered non-native disulfide bond (s) between the TCR C1 and C2 regions. The positions of C1 and C2 regions can also be exchanged.
The antibodies to be conjugated herein are not limited to bispecific antibodies that have the first and second antigen-binding moieties targeting different epitopes or antigens. Theoretically, the antibodies to be conjugated herein could also be monospecific antibodies wherein the first and second antigen-binding moieties bind to a same antigen or epitope, and the resultant ADCs are highly homogenous ADCs against a single antigen or epitope.
In some embodiments, from N terminus to C terminus, the antibody comprises the following structure: in the 1
st heavy chain, VH1-C1-hinge-Fc; in the 2
nd heavy chain, VH2-CH1-hinge-Fc; in the 1
st light chain, VL1-C2; and in the 2
nd light chain, VL2-CL, wherein VH1 and VL1 refer to the first VH and VL and VH2 and VL2 refer to the second VH and VL, respectively. “-” represents an operable linkage, generally via a peptide linker.
The WuXiBody may adopt various other formats. For example, the heavy chain portion of the first antigen binding moiety may be operably linked to the second antigen binding moiety, and the latter one is further operably linked to one chain of the Fc region. Alternatively, the heavy chain portion of the first antigen binding moiety is operably linked to one chain of the Fc region, and the latter one is further operably linked to one chain of the second antigen binding moiety.
In some embodiments, from N terminus to C terminus, the antibody comprises the following structure: in the 1
st heavy chain, VH1-C1-hinge-Fc-scFv; in the 2
nd heavy chain, VH1-CH1-hinge-Fc-scFv; in the 1
st light chain, VL1-C2; and in the 2
nd light chain, VL1-CL. The scFv belongs to the second antigen-binding moiety and can also be replaced by a VHH format.
The first TCR constant region and the second TCR constant region are associated via a non-native interchain disulfide bond. The pair of TCR constant regions in the first antigen-binding moiety includes TCR alpha and beta constant regions (wild-type or preferably engineered) in the light chain and heavy chain respectively. The TCR constant regions in the bispecific antibodies are capable of associating with each other to form a dimer through a non-native disulfide bond.
Human TCR beta chain constant region has two different variants, known as TRBC1 and TRBC2 (IMGT nomenclature) . In WuXiBody, the sequence of TCR beta domain is based on wild type TCR sequence as:
LEDLKNVFPP
KVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGV
STDPQPLKEQPAL
NDSRY
CLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGR (SEQ ID NO: 1) , with the NCBI accession number of A0A5B9 (https: //www. uniprot. org/uniprot/A0A5B9) .
In some specific embodiments, the pair of TCR constant regions comprises an engineered TCR beta domain comprising one or more mutated sites, as shown below:
Human TCR alpha chain constant region is known as TRAC, with the NCBI accession number of P01848 (https: //www. uniprot. org/uniprot/P01848) , the sequence of wild type TCR alpha domain is:
In some specific embodiments, the pair of TCR constant regions comprises an engineered TCR alpha chain constant region comprising one or more mutated sites, as shown below:
A person in the art would easily appreciate that, the antibody for preparing ADCs as disclosed herein may comprise a variety of C1 and C2 regions, as long as they can stabilize the first VH and VL regions to form the first antigen-binding moiety. Specifically, the antibodies may comprise a TCR C1 region with the amino acid sequence as shown in SEQ ID No: 2 or 7 or a variant thereof with at least 90%identity, and a TCR C2 region with the amino acid sequence as shown in SEQ ID No: 4, 8, 9 or a variant thereof with at least 90%identity. More than one pair of non-native disulfide bonds can be formed between the C1 and C2 regions to improve stability and expression level. In some embodiments, the variants of SEQ ID No: 2 or 7 comprise substitutions, additions and/or deletions of one or more amino acids compared to SEQ ID No: 2 or 7. Similarly, the variants of SEQ ID No: 4, 8, or 9 comprise substitutions, additions and/or deletions of one or more amino acids compared to SEQ ID No: 4, 8, or 9. A detailed description of C1 and C2 variants that can be utilized for constructing WuXiBody antibody format can be found in WO2022/156687, which is entirely incorporated herein by reference. Specifically, in some embodiments, the antibodies comprise a combination of C1 and C2 regions with SEQ ID Nos: 2 and 4 (for cAb1-6) , or with SEQ ID Nos: 2 and 8 (for cAb7) , or with SEQ ID Nos: 7 and 9 (for cAb8) , respectively.
For example, the native TCR beta chain contains a native cysteine residue at position 76, which is unpaired and therefore does not form a disulfide bond in a native alpha/beta TCR. In some bispecific antibodies of WuXiBody, this native cysteine residue at position 76 of TCR beta chain is mutated to an alanine residue. This may be useful to avoid incorrect intrachain or interchain pairing. In certain embodiments, the substitution in certain embodiments can improve the TCR refolding efficiencies in vitro.
Therefore, the first and the second TCR constant regions of the first antigen-binding moiety are capable of forming a dimer comprising, between the TCR constant regions (i.e., CAlpha and CBeta) , at least one non-native interchain disulfide bond that is capable of stabilizing the dimer.
The benefits provided by replacing CH1 and CL domains with TCR constant regions is significant. In the WuXiBody, the first antigen-binding moiety with at least one non-native disulfide bond can be recombinantly expressed and assembled into the desired conformation, which stabilizes the TCR constant region dimer while providing for good antigen-binding activity of the antibody variable regions. Moreover, the first antigen-binding moiety is found to well tolerate routine antibody engineering, for example, modification of glycosylation sites, and removal of some natural sequences. Furthermore, the bispecific antibodies in such format can be readily expressed and assembled with minimal or substantially no mispairing of the antigen-binding sequences due to the presence of the TCR constant regions in the first antigen-binding moiety.
Most importantly, the non-native disulfide bond in the TCR constant regions is less accessible to solvents than native disulfide bonds, thereby providing fewer binding sites (and improved homogeneity) for coupling a drug (or a drug-linker) . Besides, the non-native disulfide bonds are possibly less sensitive to reductants than native disulfide bonds.
In some embodiments, the process comprises constructing the antibody based on a parental bispecific antibody or two parental monospecific antibodies and generation of the antibody, prior to step (a) . By “based on” it is meant to derive or obtain the first and second VH and VL regions from the variable regions of the parental antibodies and assemble into the WuxiBody format with other regions e.g. TCR constant regions, heavy and light chain constant regions, hinge regions and Fc regions.
The BsAbs to be used for conjugation comprise two antigen-binding moieties which may be a Fab, Fab’, scFv, VHH etc. The antigen-binding moiety may be derived from an antibody (already known or developed de novo) targeted to a certain antigen. In some embodiments, the first antigen-binding moiety is derived from Trastuzumab and the second antigen-binding moiety is derived from Pertuzumab, or vice versa. In some other embodiments, the first antigen-binding moiety is derived from Trastuzumab and the second antigen-binding moiety is derived from Sacituzumab, or vice versa. By “derived from” , it is generally meant herein that the antigen-binding moiety comprises the CDR sequences of the parent antibody, and preferably, comprises the variable regions of the parent antibody. In some embodiments, the antigen-binding moiety comprises the variants of the CDR sequences of the parent antibody which retain the antigen-binding specificity.
Theoretically, the parent antibodies that can derive the antigen-binding moieties can include all monoclonal antibodies that have specificity for a certain antigen, such as antibodies against tumor related antigens or pathways, e.g. PD-1/PD-L1, TIM-3, LAG-3, VEGF, HER2, CTLA-4, BMPR1B, E16, STEAP1, MUC16, MPF, Napi2b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, HER2, NCA, MDP, IL20Ra, Brevican, EphB2R, ASLG659, PSCA, GEDA, BAFF-R, CD22, CD79a, CXCR5, HLA-DOB, P2X5, CD72, LY64, FcRH1, FcRH5, TENB2, PMEL17, TMEFF1, GDNF-Ra1, Ly6E, TMEM46, Ly6G6D, LGR5, RET, Ly6K, GPR19, GPR54, ASPHD1, Tyrosinase, TMEM118, GPR172A, CD33 and CLL-1; antibodies against leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD58, CD80, CD86 or their ligands; CD3 engager antibodies, NK engager antibodies; ADCC enabling anti-Tumor associated antigens; monoclonal antibodies to TNF, among others. The antibodies may include but not limited to, trastuzumab, pertuzumab, sacituzumab, abciximab, adalimumab, alefacept, alemtuzumab, basiliximab, belimumab, bezlotoxumab, canakinumab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, golimumab, inflectra, ipilimumab, ixekizumab, natalizumab, nivolumab, olaratumab, omalizumab, palivizumab, panitumumab, pembrolizumab, rituximab, tocilizumab, trastuzumab, secukinumab, and ustekinumab.
The bispecific antibody used in the method provided herein may be antibodies that have binding specificity for a numerous variety of antigens, such as tumor associated antigens (TAA) . In certain embodiments, the bispecific antibodies to be conjugated have a first specificity for a first TAA antigen, and a second specificity for a second TAA antigen. The term “tumor associated antigen” refers to a target antigen expressed by tumor cells, however may be expressed by the cognate cell (or healthy cells) prior to transforming into a tumor. In some embodiments, the tumor associated antigens can be presented only by tumor cells and not by normal, i.e. non-tumor cells. In some other embodiments, the tumor associated antigens can be exclusively expressed on tumor cells or may represent a tumor specific mutation compared to non-tumor cells. In some other embodiments, the tumor associated antigens can be found in both tumor cells and non-tumor cells, but is overexpressed on tumor cells when compared to non-tumor cells or are accessible for antibody binding in tumor cells due to the less compact structure of the tumor tissue compared to non-tumor tissue. In some embodiments, the tumor associated antigen is located on the vasculature of a tumor.
Illustrative examples of a tumor associated antigen are LAG-3, CD10, CD19, CD20, CD22, CD21, CD22, CD25, CD30, CD33, CD34, CD37, CD44v6, CD45, CD133, Fms-like tyrosine kinase 3 (FLT-3, CD135) , chondroitin sulfate proteoglycan 4 (CSPG4, melanoma-associated chondroitin sulfate proteoglycan) , Epidermal growth factor receptor (EGFR) , Her2neu, Her3, IGFR, IL3R, fibroblast activating protein (FAP) , CDCP1, Derlin1, Tenascin, frizzled 1-10, the vascular antigens VEGFR2 (KDR/FLK1) , VEGFR3 (FLT4, CD309) , PDGFR-alpha (CD140a) , PDGFR-beta (CD140b) Endoglin, CLEC14, Tem1-8, and Tie2. Further examples may include A33, CAMPATH-1 (CDw52) , Carcinoembryonic antigen (CEA) , Carboanhydrase IX (MN/CA IX) , de2-7 EGFR, EGFRvIII, EpCAM, Ep-CAM, Folate-binding protein, G250, Fms-like tyrosine kinase 3 (FLT-3, CD135) , c-Kit (CD117) , CSF1R (CD115) , HLA-DR, IGFR, IL-2 receptor, IL3R, MCSP (Melanoma-associated cell surface chondroitin sulphate proteoglycane) , Muc-1, Prostate-specific membrane antigen (PSMA) , Prostate stem cell antigen (PSCA) , Prostate specific antigen (PSA) , and TAG-72.
In certain embodiments, the bispecific antibodies provided herein have a first specificity for a TAA antigen, and a second specificity for an infectious disease-associated antigen or an epitope thereof. Non-limiting examples of infectious disease-associated antigens include, e.g., an antigen that is expressed on the surface of a virus particle, or preferentially expressed on a cell that is infected with a virus, wherein the virus is selected from the group consisting of HIV, hepatitis (A, B or C) , herpes virus (e.g., HSV-1 , HSV-2, CMV, HAV-6, VZV, Epstein Barr virus) , adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus, and arboviral encephalitis virus. Alternatively, the target antigen can be an antigen that is expressed on the surface of a bacterium, or preferentially expressed on a cell that is infected with a bacterium, wherein the bacterium is selected from the group consisting of chlamydia, rickettsia, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci, gonococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospira, and Lyme disease bacteria. In certain embodiments, the target antigen is an antigen that is expressed on the surface of a fungus, or preferentially expressed on a cell that is infected with a fungus, wherein the fungus is selected from the group consisting of Candida (albicans, krusei, glabrata, tropicalis, etc. ) , Crytococcus neoformans, Aspergillus (fumigatus, niger, etc. ) , Mucorales (mucor, absidia, rhizopus, etc. ) , Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and Histoplasma capsulatum. In certain embodiments, the target antigen is an antigen that is expressed on the surface of a parasite, or preferentially expressed on a cell that is infected with a parasite, wherein the parasite is selected from the group consisting of Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, Nippostrongylus brasiliensis, Taenia crassiceps, and Brugia malayi. Non-limiting examples of specific pathogen-associated antigens include, e.g., HIV gp120, HIV CD4, hepatitis B glucoprotein L, hepatitis B glucoprotein M, hepatitis B glucoprotein S, hepatitis C E1, hepatitis C E2, hepatocyte-specific protein, herpes simplex virus gB, cytomegalovirus gB, and HTLV envelope protein.
The WuXiBody BsAb to be conjugated herein may further comprise a knob-into-hole structure in the Fc region. An extra inter-chain disulfide bond is created in the knob-hole region to increase the stability of the bispecific antibody. With 5 pairs of inter-chain disulfide bonds in such BsAbs, it is found that under normal TCEP reduction, only 3 pairs of the bonds will be broken to react with maleimide-modified drug to give DAR6 enriched (>90%) ADC. The other 2 pairs of non-native disulfide bonds (in the TCR region and Fc region) are structurally not exposed to reducing agent and thus cannot be opened for drug attachment. In the circumstances where C1 and C2 regions form more than one non-native disulfide bonds, they are also structurally inaccessible to reducing agents.
In some embodiments, the bispecific antibodies to be conjugated herein comprise two heavy chains and two light chains, wherein from N terminal to C terminal:
the first heavy chain comprises domains operably linked as in VH1-C1-hinge-Fc and the first light chain comprises domains operably linked as in VL1-C2; the second heavy chain comprises domains operably linked as in VH2-CH1-hinge-Fc and the second light chain comprises domains operably linked as in VL2-CL, wherein VH1 and VL1 refer to the first heavy chain and light chain variable regions derived from a first parental antibody, while VH2 and VL2 refer to the second heavy chain and light chain variable regions derived from a first parental antibody. VH1, C1, VL1 and C2 constitute the first antigen binding moiety, and VH2, CH1, VL2 and CL constitute the second antigen binding moiety.
Conjugation process for preparing ADCs with high homogeneity of D6
In one aspect, the disclosure provides a process for preparing a highly homogeneous (occupies more than 50%, 60%, 70%, 80%, 90%or higher of total produced ADCs) antibody-drug conjugate (ADC) for the bispecific antibody as described above, the process comprises the following steps:
(a) incubating a reductant and the bispecific antibody in a buffer system; and
(b) introducing an excess amount of a linker-drug moiety (e.g. MC-MMAF) to react with reduced thiol groups resulted from step (a) ; and
(c) recovering the resultant antibody-drug conjugate.
Optionally, the process further comprises adding an effective amount of oxidant to re-oxidize the unreacted thiol groups after step (b) .
As described above, the bispecific antibody to be conjugated is constructed as a knob-into-hole bispecific antibody with a TCR arm and a normal IgG Fab at its variable regions. An extra inter-chain disulfide bond is created in the knob-hole region to increase the stability of the bispecific antibody. With 5 pairs of inter-chain disulfide bonds, it is found that under normal TCEP reduction, only 3 pairs of the bonds will be broken to react with drugs (e.g. maleimide-modified drug) , giving a DAR6 enriched (>80%, or even 90%) ADC.
In other words, conjugation with bispecific antibodies in WuXiBody form generate highly homogeneous DAR6 (D6) species with 85~95%purity, although the antibody contains 5 pairs of inter-chain disulfide bonds. Two pairs of non-native disulfide bonds, one in the TCR constant regions and the other in the “knob-hole” structure, are not reduced by the reductant, which leaves only 3 pairs of disulfide bonds for reduction and site-specific conjugation. Among which, two pairs are in the hinge region and the other pair is in the CH1-CL region of the second antigen-binding moiety.
In the resultant ADCs, the content of D6 ADCs can reach at least 80 wt%, for example, at least 85 wt%, at least 90 wt%, at least 91 wt%, at least 92 wt%or at least 93 wt%, on the basis of total weight of D0, D2, D4 and D6, as measured by HIC.
In some embodiments, the reductant may be TCEP. The concentration of the reductant in the reaction solution may be 0.04 mM to 0.4 mM.
In some embodiments, the oxidant to be added may be DHAA. The concentration of the oxidant in the reaction solution may be 0.08 mM to 0.8 mM.
The optimum pH for the reaction will typically be between about 5.5 and about 8, for instance, about 5.5 to 7.5. The optimal reaction conditions will of course depend upon the specific reactants employed.
In an embodiment, the buffer is PBS, pH 7.
The optimum temperature for the reduction reaction and conjugation reaction will typically be between about -10℃ and 37℃, e.g. about 4℃-22℃. For instance, the reduction reaction occurs at a temperature of about 22℃ for 8-18 h, and the conjugation reaction occurs at a temperature of about 4℃ overnight. The temperature and time may vary depending on the amounts of antibody, reductant and drugs used.
Those skilled in the art should understand that the incubation time period and temperature in step (a) depend on specific antibodies to be conjugated. The determination of the incubation time period and temperature based on specific antibodies is within the abilities of ordinary skilled persons in the art. For example, the antibody to be conjugated is typically incubated with the reductant at 4℃ overnight.
In some embodiments, the concentration of the bispecific antibody in the reaction is from 0.01 mM to 0.1 mM. In a specific embodiment, the concentration of the antibody is 0.02 mM.
As for step (c) , those skilled in the art can select proper purification methods to recover the resultant antibody-drug conjugates. Many ADC purification methods are well known in the art. For example, the resultant antibody-drug conjugates may be purified by using a de-salting column, size exclusion chromatography, and the like.
In some embodiments, the resultant antibody-drug conjugates are recovered by any suitable purification method, such as using a de-salting column, size exclusion chromatography, ultrafiltration, dialysis, UF-DF, and the like.
Conjugation process for preparing ADCs with high homogeneity of D2
Transitional metal ions and/or divalent metal ions could protect the disulfide bonds in the hinge region from being reduced during the incubation of the reductant and the antibody. The inventors herein combined such metal ion chelating function with WuXiBody antibody for ADC conjugation, giving very narrow DAR2 distribution which allows the preparation of ADCs of low DAR. When drugs (such as PBD) are highly potent and too high DARs lead to toxicity issues, ADCs of low DAR are desired.
When a metal ion such as Zn (II) is added into the reaction system, two disulfide bonds in the hinge region are shielded from the reducing agent and only one pair of the disulfide bond in the CH1-CL region of the IgG side is reduced, and only DAR2 species is generated upon drug addition. The PK/PD properties of ADC of such highly homogeneous D2 population rivals that generated by antibody engineering. The manufacture of such ADC is also easy. The low-DAR ADC is of great importance when low DAR is required, e.g. when the drug is too toxic for high loading.
Thus, in one aspect, the disclosure provides a process for preparing an antibody-drug conjugate (ADC) for the bispecific antibody as described above, wherein the process comprises the following steps:
(a) incubating a reductant and the bispecific antibody in the presence of an effective amount of metal ions such as transition metal ions and divalent metal ions in a buffer system to selectively reduce inter-chain disulfide bonds within the antibody;
(b) introducing an excess amount of a linker-drug moiety (e.g. MC-MMAF) to react with reduced thiol groups resulted from step (a) ; and
(c) recovering the resultant antibody-drug conjugate.
Optionally, the process further comprises adding an effective amount of oxidant to re-oxidize the unreacted thiol groups after step (b) .
In some embodiments, the reductant may be TCEP. The concentration of the reductant in the reaction solution may be 0.04 mM to 0.4 mM. The oxidant to be added after step (b) may be DHAA. The concentration of the oxidant in the reaction solution may be 0.08 mM to 0.8 mM.
In some embodiments, the metal ion which is suitable to be used in the bio-conjugation process of the present disclosure is selected from transition metal ions and divalent ions, including but not limited to, Zn2+, Cd2+, Ca2+, Mg2+ and Hg2+, and the like. Among others, Zn2+ is used due to its easy availability and low cost. For example, suitable transition metal salts may be added in step (a) as long as they are soluble in the reaction solution so that free transition metal ions can be released in the reaction solution. In this regard, ZnCl2, Zn (NO3) 2, ZnSO4, Zn (CH3COO) 2, ZnI2, ZnBr2, Zinc Formate, and zinc tetrafluoroborate may be mentioned as suitable zinc salts. Likewise, other transition metal salts which are soluble and can release free Cd2+ or Hg2+ ions in the reaction solution can be mentioned, which include, but not limited to, CdCl2, Cd (NO3) 2, CdSO4, Cd (CH3COO) 2, CdI2, CdBr2, cadmium formate, and cadmium tetrafluoroborate; HgCl2, Hg(NO3) 2, HgSO4, Hg (CH3COO) 2, HgBr2, Mercury (II) formate, and Mercury (II) tetrafluoroborate; and the like. Those skilled in the art can make a selection from the above transition metal salts and divalent metal salts as the source of metal ions.
In an embodiment, Zn2+ is used in step (a) . Zinc salts which are water soluble are available. For example, ZnCl2 may be added in step (a) as the Zn2+ source.
The concentration of the metal ions in the reaction solution in step (a) is 0.01 mM to 0.2 mM.
The metal ions will be removed in purification step by using EDTA as chelating reagent, which will be filtered out in subsequent dialysis, ultrafiltration or gel filtration.
Depending on the metal ions, those skilled in the art can select suitable buffer system for the reaction in step (a) , including, but not limited to, Hepes, Histidine buffer, PBS, MES, and the like. In a specific embodiment, the buffer system used in step (a) is PBS.
The optimum pH for the reaction will typically between about 5.5 and about 8, for instance, about 5.5 to 7.5. The optimal reaction conditions will of course depend upon the specific reactants employed.
In an embodiment, the buffer is PBS, pH 7.
The optimum temperature for the reduction reaction and conjugation reaction will typically be between about -10℃ and 37℃, e.g. about 4℃-22℃. For instance, the reduction reaction occurs at a temperature of about 4℃ overnight, and the conjugation reaction occurs at a temperature of about 4℃ for 2-8 h. The temperature and time may vary depending on the amounts of antibody, reductant and drugs used.
For instance, the antibody to be conjugated, the metal ions and the reductant may be present in the reaction mixture in a ratio of 1: 2: 4 in molar concentration. In one embodiment, 0.02 mM antibody is incubated with 0.08 mM TCEP and 0.04 mM ZnCl2 at 4℃ overnight. It will be understood by a person skilled in the art that a molar concentration may also be converted into “eq” compared to antibody. For instance, “0.04 mM ZnCl2” may be converted into “2 eq ZnCl2” if antibody is used at 0.02 mM.
In the resultant ADCs, the content of D2 ADCs can reach at least 80 wt%, for example, at least 85 wt%, at least 90 wt%, at least 91 wt%, at least 92 wt%, at least 93 wt%, at least 94 wt%, or at least 95 wt%on the basis of total weight of D0 and D2, as measured by HIC.
Conjugation process for preparing bi-drug ADCs with high homogeneity of D2+4
Combining drugs with different mechanisms of action for treatment is often beneficial and may improve treatment outcomes. Although the targeted approach of an ADC typically yields favorable results, (acquired) drug resistance often emerges, limiting the effectiveness of ADCs. One way to circumvent the problem of ADC-associated drug resistance is combining ADCs with different drugs or using ADCs with multiple-drug payloads. In one aspect, the present disclosure provides a process for producing highly homogeneous (more than 50%, 60%, 70%, 80%, 90%or higher of total produced ADCs) ADCs with two different payloads.
Based on the above two processes, a two-step conjugation –with the presence of effective amount of metal ions for conjugation of the first drug moiety and without such metal ions for conjugation of the second drug moiety -is developed and produces a highly homogeneous ADC of DAR (2+4) . Such bi-drug ADCs are more resistant to multi-drug resistance of cancer cells rising from cancer therapies and can be easily produced by this conjugation process. The designation of “DAR (a+b) ” or “D (a+b) ” herein refers to a bi-drug ADC in which the number of the first drug conjugated to a single antibody molecule is “a” and the number of the second drug conjugated to the antibody molecule is “b” .
Thus, in one aspect, the disclosure provides a process for preparing an antibody-drug conjugate (ADC) of the bispecific antibodies as described above, wherein the process comprises the following steps:
(a) incubating a reductant and the bispecific antibody in the presence of an effective amount of metal ions such as transition metal ions and divalent metal ions in a buffer system to selectively reduce inter-chain disulfide bonds within the antibody;
(b) introducing an excess amount of a first linker-drug moiety to react with reduced thiol groups resulted from step (a) ;
(c) removing the metal ions from the product of step (b) ;
(d) adding a reductant again and incubating with an excess amount of a second linker-drug moiety; and
(e) recovering the resultant antibody-drug conjugate.
Optionally, the process further comprises adding an effective amount of oxidant to re-oxidize the unreacted thiol groups after step (d) .
The reductant, metal ions, buffer systems and oxidants may be the same as disclosed above for preparing D2 ADC. For step (c) , the metal ions can be removed in purification step by using EDTA as chelating reagent, which will be filtered out in subsequent dialysis, ultrafiltration or gel filtration.
The reaction conditions for reducing and conjugation may be the same as disclosed above for preparing D2 ADC. The optimum temperature for the reduction reaction and conjugation reaction will typically be between about -10℃ and 37℃, e.g. about 4℃-22℃. The second reduction and conjugation of steps (c) and (d) may have slight differences from steps (a) and (b) . For instance, the reduction reaction for step (c) occurs at a temperature of about 22℃ for 2-8h, and the conjugation reaction occurs at about 22℃ for 2-8 h. The temperature and time may vary depending on the amounts of antibody, reductant and drugs used.
In some embodiments, the first linker-drug moiety is MC-MMAF and the second linker-drug moiety is MC-DXD or DXD with other linkers.
In the resultant ADCs, the content of D2+4 ADCs can reach at least 80 wt%, for example, at least 85 wt%, at least 90 wt%, at least 91 wt%, at least 92 wt%, at least 93 wt%, at least 94 wt%, or at least 95 wt%on the basis of total weight of D0, D2, D2+2 and D4, as calculated from MS analysis.
Highly homogenous ADC of Bispecific Antibody Shows Better Efficacy
The main problem of conventional conjugation of ADC is the heterogeneity of the ADC molecules where the drug moieties are attached at several sites on the antibody, for example, ranging from 0 to 8 per antibody (Drug-Antibody Ratio, DAR) by cysteine chemistry. ADC molecules of such a mixture not only brings difficulties in analysis and characterization, but also potentially has different pharmacokinetic, distribution, toxicity and efficacy profiles. And non-specific conjugation also frequently results in impaired antibody function. Therefore, narrow distribution of DAR is desired for better PK, efficacy and therapeutic window.
In one aspect, the present disclosure provides a highly homogeneous antibody-drug conjugates of bispecific antibodies, wherein the D6 ADC constitute more than 80 wt%of the ADCs.
In one aspect, the present disclosure provides a highly homogeneous antibody-drug conjugates of bispecific antibodies, wherein the D2 ADC constitute more than 80 wt%of the ADCs.
In one aspect, the present disclosure provides a highly homogeneous antibody-drug conjugates of bispecific antibodies, wherein the D2+4 ADC constitute more than 80 wt%of the ADCs.
In some embodiments, the homogeneity of the antibody-drug conjugates generated by the process as disclosed herein is measured and compared with the homogeneity of corresponding control antibody-drug conjugates generated by conventional conjugation processes.
Various analytical methods can be used to determine the yields and isomeric mixtures of the antibody-drug conjugates. For example, in one embodiment, HIC is the analytical method used to determine yields and isomeric mixtures from resultant antibody-drug conjugates (e.g., for D6 conjugates) . This technique is able to separate antibodies loaded with various numbers of drugs. The drug loading level can be determined based on the ratio of absorbances, e.g., at 250 nm and 280 nm. For example, if a drug can absorb at 250 nm while the antibody absorbs at 280 nm. The 250/280 ratio therefore increases with drug loading. Using the bio-conjugation process described herein, generally antibodies with even numbers of drugs were observed because conjugation incompletion leads to even number of DAR.
Linker-Drug moiety
The use of antibody-drug conjugates for local delivery of cytotoxic or cytostatic agents, i.e. drugs to kill or inhibit tumor cells in the treatment of cancer allows targeted delivery of the drug moiety to tumors, and intracellular accumulation therein, where systemic administration of unconjugated drug agents may result in unacceptable levels of toxicity to normal cells as well as the tumor cells sought to be eliminated (Thorpe, (1985) "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review, " in Monoclonal Antibodies '84: Biological And Clinical Applications, A. Pinchera et al. (ed. s) , pp. 475-506) . Both polyclonal antibodies and monoclonal antibodies have been reported as useful in these strategies (Rowland et al., (1986) Cancer Immunol. Immunother., 21: 183-87) .
Drugs that can be used in ADCs include chemotherapeutic agents such as daunomycin, doxorubicin, methotrexate, and vindesine; toxins, for example bacterial toxins such as diphtheria toxin, plant toxins such as ricin, small molecule toxins such as geldanamycin, maytansinoids, and calicheamicin; auristatin peptides, auristatin E (AE) and monomethylauristatin (MMAE) , which are synthetic analogs of dolastatin. MMAE is a synthetic derivative of dolastatin 10, a natural cytostatic pseudo peptide. The toxins may achieve their cytotoxic and cytostatic effects by mechanisms including tubulin binding, DNA binding, or topoisomerase inhibition. Some cytotoxic drugs tend to be inactive or less active when conjugated to large antibodies or protein receptor ligands.
There are no specific limitations to the drug and linker which can be used in the conjugation process of the present disclosure, as long as the drug molecule has an antitumor, antiviral or antimicrobial effect and contains at least one substituted group or a partial structure allowing connection to a linker structure, and the linker contains at least two reactive groups, one of which can covalently bond a drug molecule and the other of which can covalently couple to an antibody. Preferably, the linker is susceptible to –SH attack from the antibody and capable of forming a linkage with the antibody.
Depending on the desired drug and selected linker, those skilled in the art can select suitable method for coupling them together. For example, some conventional coupling methods, such as amine coupling methods, may be used to form the desired drug-linker complex which still contains reactive groups for conjugating to the antibodies through covalent linkage. A drug-maleimide complex (i.e., maleimide linking drug) is taken as an example of the payload bearing reactive group in the present disclosure.
In an embodiment, the drug may include, but not limited to, cytotoxic reagents, such as chemo-therapeutic agents, immunotherapeutic agents and the like, antiviral agents or antimicrobial agents. In an embodiment, the drug to be conjugated with an antibody may be selected from, but not limited to, MMAE (monomethyl auristatin E) , MMAD (monomethyl auristatin D) , MMAF (monomethyl auristatin F) , and the like.
Most common reactive group capable of bonding to thiol group in ADC preparation is maleimide. Additionally, organic bromides, iodides also are frequently used.
Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, non-binding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa) , ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S) , momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. See, e.g., WO 93/21232 published October 28, 1993. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 212Bi, 131I, 131In, 90Y, and 186Re. One or more small molecule toxins, such as a calicheamicin, maytansinoids, dolastatins, auristatins, a trichothecene, and CC1065, and the derivatives of these toxins that have toxin activity, can be conjugated with the antibody by the process as disclosed herein.
Maytansine compounds suitable for use as maytansinoid drug moieties are well known in the art and can be isolated from natural sources according to known methods, produced using genetic engineering techniques (see Yu et al (2002) PNAS 99: 7968-7973) , or maytansinol and maytansinol analogues prepared synthetically according to known methods. Suitable maytansinoids are disclosed, for example, in U.S. Patent No. 5,208,020. Preferred maytansinoids are maytansinol and maytansinol analogues modified in the aromatic ring or at other positions of the maytansinol molecule, such as various maytansinol esters.
Dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cellular division and have anticancer and antifungal activity (Pettit et al (1998) Antimicrob. Agents Chemother. 42: 2961-2965) . The dolastatin or auristatin drug moiety may be attached to the antibody through the N (amino) terminus or the C (carboxyl) terminus of the peptidic drug moiety (WO 02/088172) . Exemplary embodiments comprising MMAE or MMAF and various linker components are shown below. For example, VcMMAE (Mc-vc-PAB-MMAE) is obtained by using MMAE linked via p-aminobenzyloxycarbonyl ( “PAB” ) to the lysosomally cleavable dipeptide valine-citrulline (vc) and a thiolreactive maleimidocaproyl spacer (MC) .
Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3- (2-pyridyldithiol) propionate (SPDP) , iminothiolane (IT) , bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl) , active esters (such as disuccinimidyl suberate) , aldehydes (such as glutaraldehyde) , bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine) , bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl) -ethylenediamine) , diisocyanates (such as toluene 2, 6-diisocyanate) , and bis-active fluorine compounds (such as 1, 5-difluoro-2, 4-dinitrobenzene) . For example, a ricin immunotoxin can be prepared as described in Vitetta et al (1987) Science, 238: 1098. Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody (WO94/11026) .
Additional exemplary embodiments comprising MMAE or MMAF and various linker components. For example, VcMMAE (Mc-vc-PAB-MMAE) is obtained by using MMAE linked via p-aminobenzyloxycarbonyl ( “PAB” ) to the lysosomally cleavable dipeptide valine-citrulline (vc) and a thiolreactive maleimidocaproyl spacer (MC) .
Pharmaceutical Composition
In one aspect, the present disclosure relates to a pharmaceutical composition comprising an effective amount of the ADCs with improved homogeneity prepared by the process as disclosed herein and a pharmaceutically acceptable carrier or vehicle. The compositions are suitable for veterinary or human administration.
The compositions of the present disclosure can be in any form that allows for the composition to be administered to an animal. For example, the composition can be in the form of a solid, liquid or gas (aerosol) . Typical routes of administration include, without limitation, oral, topical, parenteral, sublingual, rectal, vaginal, ocular, and intranasal. Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. For example, the compositions are administered parenterally. Pharmaceutical compositions of the invention can be formulated so as to allow ADCs of the disclosure to be bioavailable upon administration of the composition to an animal. Compositions can take the form of one or more dosage units, where for example, a tablet can be a single dosage unit, and a container of ADCs of the disclosure in aerosol form can hold a plurality of dosage units.
Materials used in preparing the pharmaceutical compositions can be non-toxic in the amounts used. It will be evident to those of ordinary skill in the art that the optimal dosage of the active ingredient (s) in the pharmaceutical composition will depend on a variety of factors. Relevant factors include, without limitation, the type of animal (e.g., human) , the particular form of the ADCs, the manner of administration, and the composition employed.
Suitable components may include, for example, antioxidants, fillers, binders, disintegrants, buffers, preservatives, lubricants, flavorings, thickeners, coloring agents, emulsifiers or stabilizers such as sugars and cyclodextrins. Suitable antioxidants may include, for example, methionine, ascorbic acid, EDTA, sodium thiosulfate, platinum, catalase, citric acid, cysteine, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxanisol, butylated hydroxytoluene, and/or propyl gallate. As disclosed herein, inclusion of one or more antioxidants such as methionine in a pharmaceutical composition provided herein decreases oxidation of the polypeptide complex or the bispecific polypeptide complex. This reduction in oxidation prevents or reduces loss of binding affinity, thereby improving protein stability and maximizing shelf-life. Therefore, in certain embodiments, compositions are provided that comprise the polypeptide complex or the bispecific polypeptide complex disclosed herein and one or more antioxidants such as methionine.
To further illustrate, pharmaceutical acceptable carriers may include, for example, aqueous vehicles such as sodium chloride injection, Ringer’s injection, isotonic dextrose injection, sterile water injection, or dextrose and lactated Ringer’s injection, non-aqueous vehicles such as fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil, or peanut oil, antimicrobial agents at bacteriostatic or fungistatic concentrations, isotonic agents such as sodium chloride or dextrose, buffers such as phosphate or citrate buffers, antioxidants such as sodium bisulfate, local anesthetics such as procaine hydrochloride, suspending and dispersing agents such as sodium carboxymethylcelluose, hydroxypropyl methylcellulose, or polyvinylpyrrolidone, emulsifying agents such as Polysorbate 80 (TWEEN-80) , sequestering or chelating agents such as EDTA (ethylenediaminetetraacetic acid) or EGTA (ethylene glycol tetraacetic acid) , ethyl alcohol, polyethylene glycol, propylene glycol, sodium hydroxide, hydrochloric acid, citric acid, or lactic acid. Antimicrobial agents utilized as carriers may be added to pharmaceutical compositions in multiple-dose containers that include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride. Suitable excipients may include, for example, water, saline, dextrose, glycerol, or ethanol. Suitable non-toxic auxiliary substances may include, for example, wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, or agents such as sodium acetate, sorbitan monolaurate, triethanolamine oleate, or cyclodextrin.
The pharmaceutical compositions can be a liquid solution, suspension, emulsion, pill, capsule, tablet, sustained release formulation, or powder. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinyl pyrollidone, sodium saccharine, cellulose, magnesium carbonate, etc.
In certain embodiments, the pharmaceutical compositions are formulated into an injectable composition. The injectable pharmaceutical compositions may be prepared in any conventional form, such as for example liquid solution, suspension, emulsion, or solid forms suitable for generating liquid solution, suspension, or emulsion. Preparations for injection may include sterile and/or non-pyretic solutions ready for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use, and sterile and/or non-pyretic emulsions. The solutions may be either aqueous or non-aqueous.
In certain embodiments, unit-dose parenteral preparations are packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration should be sterile and not pyretic, as is known and practiced in the art.
In certain embodiments, a sterile, lyophilized powder is prepared by dissolving the ADCs as disclosed herein in a suitable solvent. The solvent may contain an excipient which improves the stability or other pharmacological components of the powder or reconstituted solution, prepared from the powder. Excipients that may be used include, but are not limited to, water, dextrose, sorbital, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agents. The solvent may contain a buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, in one embodiment, about neutral pH. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides a desirable formulation. In one embodiment, the resulting solution will be apportioned into vials for lyophilization. Each vial can contain a single dosage or multiple dosages of the ADCs provided herein or composition thereof. Overfilling vials with a small amount above that needed for a dose or set of doses (e.g., about 10%) is acceptable so as to facilitate accurate sample withdrawal and accurate dosing. The lyophilized powder can be stored under appropriate conditions, such as at about 4 ℃ to room temperature.
Reconstitution of a lyophilized powder with water for injection provides a formulation for use in parenteral administration. In one embodiment, for reconstitution the sterile and/or non-pyretic water or other liquid suitable carrier is added to lyophilized powder. The precise amount depends upon the selected therapy being given and can be empirically determined.
Additionally, the antibody-drug conjugates or the pharmaceutical composition may be manufactured into a kit, including an insert which indicates the information for the application, such as the indications, the amount in use, the route to be administrated, and the like.
Use of the ADCs with Improved Homogeneity
In one aspect, the present disclosure relates to the use of the antibody-drug conjugates with improved homogeneity prepared by the process of the first aspect in the manufacture of a pharmaceutical composition or a kit for treating a condition or disorder in a subject.
The subject may be a mammal, for example, a human.
The condition or disorder to be treated may be a tumor, cancer, autoimmune disease, or infectious disease. In specific embodiments, the infectious disease may be viral or microbial infection.
In one aspect, the present disclosure also relates to a method for treating a subject having a condition or disorder, comprising: administrating a therapeutically effective amount of the ADCs with improved homogeneity prepared by the process as disclosed herein or a therapeutically effective amount of the pharmaceutical composition comprising the ADCs with improved homogeneity prepared by the process as disclosed herein to a subject in need thereof, thereby treating or preventing the condition or disorder.
In certain embodiments, the subject has been identified as having a condition or disorder likely to respond to the ADCs provided herein.
The subject may be a mammal, for example, a human.
The condition or disorder to be treated may be a tumor, cancer, autoimmune disease, or infectious disease. In specific embodiments, the infectious disease may be viral or microbial infection.
The therapeutically effective amount of the ADCs provided herein will depend on various factors known in the art, such as for example body weight, age, past medical history, present medications, state of health of the subject and potential for cross-reaction, allergies, sensitivities and adverse side-effects, as well as the administration route and extent of disease development. Dosages may be proportionally reduced or increased by one of ordinary skill in the art (e.g., physician or veterinarian) as indicated by these and other circumstances or requirements.
In certain embodiments, the ADCs or pharmaceutical composition provided herein may be administered at a therapeutically effective dosage of about 0.01 mg/kg to about 100 mg/kg (e.g., about 0.01 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, or about 100 mg/kg) . In certain of these embodiments, the ADCs or pharmaceutical composition provided herein are administered at a dosage of about 50 mg/kg or less, and in certain of these embodiments the dosage is 10 mg/kg or less, 5 mg/kg or less, 1 mg/kg or less, 0.5 mg/kg or less, or 0.1 mg/kg or less. In certain embodiments, the administration dosage may change over the course of treatment. For example, in certain embodiments the initial administration dosage may be higher than subsequent administration dosages. In certain embodiments, the administration dosage may vary over the course of treatment depending on the reaction of the subject.
Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic response) . For example, a single dose may be administered, or several divided doses may be administered over time.
The ADCs or pharmaceutical composition provided herein may be administered by any route known in the art, such as for example parenteral (e.g., subcutaneous, intraperitoneal, intravenous, including intravenous infusion, intramuscular, or intradermal injection) or non-parenteral (e.g., oral, intranasal, intraocular, sublingual, rectal, or topical) routes.
In certain embodiments, the condition or disorder treated by the ADCs or pharmaceutical composition provided herein is cancer or a cancerous condition, autoimmune disease or infectious disease.
The cancer may be antigen positive carcinomas including those of the lung, breast, colon, ovaries, and pancreas, for example, the cancers associated with tumor-associated antigens.
Other particular types of cancers that can be treated with the ADCs or pharmaceutical composition provided herein include, but are not limited to, solid tumors, including but not limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophogeal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms’ tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, retinoblastoma; blood-borne cancers, including but not limited to: acute lymphoblastic leukemia “ALL” , acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblastic leukemia “AML” , acute promyelocytic leukemia “APL" , acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocyctic leukemia, acute undifferentiated leukemia, chronic myelocytic leukemia “CML” , chronic lymphocytic leukemia “CLL” , hairy cell leukemia, multiple myeloma; Lymphomas: B cell lymphoma, optionally Hodgkin lymphoma or non-Hodgkin lymphoma, wherein the non-Hodgkin lymphoma comprises: Diffuse large B-cell lymphoma (DLBCL) , Follicular lymphoma, Marginal zone B-cell lymphoma (MZL) , Mucosa-Associated Lymphatic Tissue lymphoma (MALT) , Small lymphocytic lymphoma (chronic lymphocytic leukemia, CLL) , or Mantle cell lymphoma (MCL) , Acute Lymphoblastic Leukemia (ALL) , or Waldenstrom’s Macroglobulinemia (WM) .
The autoimmune disease may include, but not limited to, Active Chronic Hepatitis, Addison’s Disease, Allergic Alveolitis, Allergic Reaction, Allergic Rhinitis, Alport’s Syndrome, Anaphlaxis, Ankylosing Spondylitis, Anti-phosholipid Syndrome, Arthritis, Ascariasis, Aspergillosis, Atopic Allergy, Atropic Dermatitis, Atropic Rhinitis, Behcet’s Disease, Bird-Fancier’s Lung, Bronchial Asthma, Caplan’s Syndrome, Cardiomyopathy, Celiac Disease, Chagas’ Disease, Chronic Glomerulonephritis, Cogan’s Syndrome, Cold Agglutinin Disease, Congenital Rubella Infection, CREST Syndrome, Crohn’s Disease, Cryoglobulinemia, Cushing’s Syndrome, Dermatomyositi, Discoid Lupus, Dressler’s Syndrome, Eaton-Lambert Syndrome, Echovirus Infection, Encephalomyelitis, Endocrine opthalmopathy, Epstein-Barr Virus Infection, Equine Heaves, Erythematosis, Evan’s Syndrome, Felty’s Syndrome, Fibromyalgia, Fuch’s Cyclitis, Gastric Atrophy, Gastrointestinal Allergy, Giant Cell Arteritis, Glomerulonephritis, Goodpasture’s Syndrome, Graft v. Host Disease, Graves’ Disease, Guillain-Barre Disease, Hashimoto’s Thyroiditis, Hemolytic Anemia, Henoch-Schonlein Purpura, Idiopathic Adrenal Atrophy, Idiopathic Pulmonary Fibritis, IgA Nephropathy, Inflammatory Bowel Diseases, Insulin-dependent Diabetes Mellitus, Juvenile Arthritis, Juvenile Diabetes Mellitus (Type I) , Lambert-Eaton Syndrome, Laminitis, Lichen Planus, Lupoid Hepatitis, Lupus, Lymphopenia, Meniere’s Disease, Mixed Connective Tissue Disease, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polyglandular Syndromes, Presenile Dementia, Primary Agammaglobulinemia, Primary Biliary Cirrhosis, Psoriasis, Psoriatic Arthritis, Raynauds Phenomenon, Recurrent Abortion, Reiter’s Syndrome, Rheumatic Fever, Rheumatoid Arthritis, Sampter’s Syndrome, Schistosomiasis, Schmidt’s Syndrome, Scleroderma, Shulman’s Syndrome, Sjorgen’s Syndrome, Stiff-Man Syndrome, Sympathetic Ophthalmia, Systemic Lupus Erythematosis, Takayasu’s Arteritis, Temporal Arteritis, Thyroiditis, Thrombocytopenia, Thyrotoxicosis, Toxic Epidermal Necrolysis, Type B Insulin Resistance, Type I Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vitiligo, Waldenstrom’s Macroglobulemia, Wegener’s Granulomatosis.
In one embodiment, the present disclosure includes a method for treating disease or disorder in a subject, comprising administering to the subject an effective amount of ADCs or pharmaceutical composition provided herein and another therapeutic agent.
In some embodiments, the therapeutic agent is an anti-cancer agent. Suitable anticancer agents include, but are not limited to, methotrexate, taxol, L-asparaginase, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, topotecan, nitrogen mustards, cytoxan, etoposide, 5-fluorouracil, BCNU, irinotecan, camptothecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine, paclitaxel, and docetaxel.
In some embodiments, the therapeutic agent is an anti-autoimmune disease agent. Suitable anti-autoimmune disease agents include, but are not limited to, cyclosporine, cyclosporine A, mycophenylate mofetil, Sirolimus, tacrolimus, etanercept, prednisone, azathioprine, methotrexate cyclophosphamide, prednisone, aminocaproic acid, chloroquine, hydroxychloroquine, hydrocortisone, dexamethasone, chlorambucil, DHEA, danazol, bromocriptine, meloxicam, and infliximab.
In some embodiments, the therapeutic agent is anti-infectious disease agent. In some embodiments, the anti-infectious disease agent is, but not limited to, antibacterial agents: [beta] -Lactam Antibiotics: Penicillin G, Penicillin V, Cloxacilliin, Dicloxacillin, Methicillin, Nafcillin, Oxacillin, Ampicillin, Amoxicillin, Bacampicillin, Azlocillin, Carbenicillin, Mezlocillin, Piperacillin, Ticarcillin; Aminoglycosides: Amikacin, Gentamicin, Kanamycin, Neomycin, Netilmicin, Streptomycin, Tobramycin; Macrolides: Azithromycin, Clarithromycin, Erythromycin, Lincomycin, Clindamycin; Tetracyclines: Demeclocycline, Doxycycline, Minocycline, Oxytetracyclinem, Tetracycline; Quinolones: Cinoxacin, Nalidixic Acid; Fluoroquinolones: Ciprofloxacin, Enoxacin, Grepafloxacin, Levofloxacin, Lomefloxacin, Norfloxacin, Ofloxacin, Sparfloxacin, Trovafloxicin; Polypeptides: Bacitracin, Colistin, Polymyxin B; Sulfonamides: Sulfisoxazole, Sulfamethoxazole, Sulfadiazine, Sulfamethizole, Sulfacetamide; Miscellaneous Antibacterial Agents: Trimethoprim, Sulfamethazole, Chloramphenicol, Vancomycin, Metronidazole, Quinupristin, Dalfopristin, Rifampin, Spectinomycin, Nitrofurantoin; Antiviral Agents: General Antiviral Agents: Idoxuradine, Vidarabine, Trifluridine, Acyclovir, Famcicyclovir, Pencicyclovir, Valacyclovir, Gancicyclovir, Foscarnet, Ribavirin, Amantadine, Rimantadine, Cidofovir, Antisense Oligonucleotides, Immunoglobulins, Inteferons; Drugs for HIV infection: Zidovudine, Didanosine, Zalcitabine, Stavudine, Lamivudine, Nevirapine, Delavirdine, Saquinavir, Ritonavir, Indinavir, Nelfinavir.
The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. All specific compositions, materials, and methods described below, in whole or in part, fall within the scope of the present invention. These specific compositions, materials, and methods are not intended to limit the invention, but merely to illustrate specific embodiments falling within the scope of the invention. One skilled in the art may develop equivalent compositions, materials, and methods without the exercise of inventive capacity and without departing from the scope of the invention. It will be understood that many variations can be made in the procedures herein described while still remaining within the bounds of the present invention. It is the intention of the inventors that such variations are included within the scope of the invention.
EXAMPLES
Now the present disclosure will be illustrated in detail with reference to the following examples. However, those skilled in the art should understand that, the following examples are only provided for illustration, but not intended to limit the present disclosure in any way.
Example 1. Generation of WuXiBody Bispecific antibodies
1.1 Construction of WuXiBody E17 format bispecific antibodies
Table 1
Antibody | Parental antibodies |
cAb1 | Trastuzumab x Pertuzumab |
cAb2 | Pertuzumab x Trastuzumab |
cAb3 | Trastuzumab x Sacituzumab |
cAb4 | Sacituzumab x Trastuzumab |
cAb5 | Sacituzumab x Cetuximab |
cAb6 | Cetuximab x Sacituzumab |
cAb7 | Trastuzumab x Pertuzumab |
cAb8 | Trastuzumab x Pertuzumab |
8 bispecific antibodies were constructed (Table 1) . The VL, VH genes (obtained from the parental antibodies in Table 1) were amplified by PCR from existing plasmid template. The TCR Cα and Cβ genes (encoding SEQ ID Nos: 2 and 4, except cAb7 and cAb8 which use different C1 and C2 region sequences shown in SEQ ID Nos: 7-9) were synthesized by Genewiz Inc (Suzhou, China) . The DNA fragments of VL
1-Cα and VL
2-CL were inserted into a linearized vector respectively, which contains a CMV promoter and a human light chain signal peptide. The DNA fragments of VH
1-Cβ were inserted into a linearized vector containing human IgG1 constant region CH2-CH3 with “knob” mutations. The DNA fragments of VH
2-CH1 were inserted into a linearized vector containing human IgG1 constant region CH2-CH3 with “hole” mutations. The vectors contain a CMV promoter and a human antibody heavy chain signal peptide. An exemplary structure of cAb1 is shown in the reaction scheme of Figure 1A.
1.2 Expression and purification of WuXiBody bispecific antibodies
Heavy chain and light chain expression plasmids were co-transfected into Expi293 cells (Invitrogen-A14527) using expression system kit (Invitrogen-A14524) according to the manufacturer’s instructions. 5 days after transfection, the supernatants were collected and used for protein purification using protein A chromatography (GE Healthcare-17543802) . If needed, further purifications were conducted using size exclusion chromatography (GE Healthcare-17104301) . Antibody concentration was measured by Nano Drop. The purity of proteins was evaluated by SDS-PAGE and HPLC-SEC.
Example 2. Conjugation to form D6 species
The reaction scheme (exemplified by cAb1) shown in Figure 1A was performed. 10 mg/mL mAb in PBS buffer was reduced by 7.5 eq TCEP and the reaction vial was stood at 22 ℃ for 8 hours. The reduced antibody solution was directly submitted to next step conjugation without TCEP removal.
DMA and Linker-payload solution (10 mg/mL stock in DMA, 18.0 eq. to antibody) was added into the reduced antibody solution. The reactions were mixed properly and the reaction vials were stood at 4 ℃ for 18 hours. The crude product was submitted to a buffer exchange into its storage buffer (1X PBS buffer, pH 7.4, Gibco) using spin desalting column (40 kD) . The resulting ADCs were submitted to do the characterizations.
Homogeneity assays. The drug/antibody ratio (DAR) and product distribution were analyzed using HIC-HPLC. Purification of D0, D2, D4, and D6 by hydrophobic interaction chromatography (HIC) was performed on a Toyopearl phenyl 650M HIC column (Tosoh Biosciences, Montgomeryville, PA) at a flow rate of 10 mL/min at ambient temperature. The column size was 1 mL per 7.5 mg of ADCs. Solvent A was 2.0 M NaCl and 50 mM sodium phosphate pH 7. Solvent B was 80%v/v 50 mM sodium phosphate pH 7 and 20%v/v acetonitrile. The column was previously equilibrated with 5 column volumes of solvent A. the ADCs were mixed with 0.67 volume of 5 M NaCl (2.0 M final) and applied to the column. D0 was not retained by the column. The different drug loaded species were eluted by sequential step gradients: D2 was eluted with 35%solvent B, D4 was eluted with 70%solvent B, D6 was eluted with 95%solvent B.
For MS analysis, 20.0 μl ADC sample solution was added with 75.0 μL 8.0 mol/L Gdn-HCl, 5.0 μL 1.0 mol/L Tris-HCl and 2.0 μL 1 mol/L DTT. The new solution was mixed well and then incubated at 10~30℃ for 10~30 min. Then the drug/antibody ratio (DAR) and product distribution were analyzed using LC-MS.
As shown in Table 2 and Figures 1B-1D, cAb1, cAb3 and cAb4 antibodies obtained ADCs with about 90%or higher homogeneity of D6 species. The other 5 antibodies achieve similar results.
Table 2: HPLC result of the homogeneity of ADCs
Lot. | mAb | Linker-payload | D6 % | |
cAb1- | cAb | 1 | MC-MMAF | 91 |
cAb3- | cAb | 3 | MC-MMAF | 90 |
cAb4- | cAb | 4 | MC-MMAF | 94 |
Example 3. Conjugation to form D2 species
3.0 eq TCEP and 1.0 eq ZnCl2 was added into mAb. The reaction vial was stood at 4 ℃ for 18 hours. DMA and Linker-payload solution (10 mg/mL stock in DMA) was added into the reduced antibody solution. The reactions were mixed properly and the reaction vials were stood at 4 ℃ for 2 hours.
Cysteine was added into the mixture. Then the new mixture was stood at 4 ℃ for 15 minutes. After 3.0 eq EDTA and 8.0 eq DHAA were added, the mixture was stood at 22 ℃ for 2 hours.
The crude product was submitted to a buffer exchange into its storage buffer (1X PBS buffer, pH 7.4, Gibco) using spin desalting column (40 kD) . The resulting ADCs (Figure 2A) were submitted to do the characterizations.
As shown in Table 3 and Figure 2B, cAb1, cAb2, cAb3 and cAb4 antibodies obtained ADCs with more than 80%homogeneity of D2 species. The other 4 antibodies achieve similar results.
Table 3
Example 4. Conjugation to form D (2+4) species
Using the reaction scheme (exemplified by cAb1) shown in Figure 3A and Table 4, the D2 ADC (mAb conjugated with Linker-payload 1) in buffer (1X PBS buffer, pH 7.4, gibco) was reduced by TCEP and the reaction vial was stood at 22 ℃ for 2 hours. The reduced antibody solution was directly submitted to next step conjugation without TCEP removal.
DMA and Linker-payload 2 solution (10 mg/mL stock in DMA) was added into the reduced antibody solution. The reactions were mixed properly and the reaction vials were stood at 22 ℃ for 2 hours.
The crude product was submitted to a buffer exchange into its storage buffer (1X PBS buffer, pH 7.4, gibco) using spin desalting column (40 kD) . The resulting ADCs were submitted to do the characterizations (Figures 3B-3E) .
As can be calculated from the MS result of Figure 3B, the content of D2+4 ADCs reach more than 90% (exemplified by cAb1) .
Table 4
Those skilled in the art will further appreciate that the present invention may be embodied in other specific forms without departing from the spirit or central attributes thereof. In that the foregoing description of the present invention discloses only exemplary embodiments thereof, it is to be understood that other variations are contemplated as being within the scope of the present invention. Accordingly, the present invention is not limited to the particular embodiments that have been described in detail herein. Rather, reference should be made to the appended claims as indicative of the scope and content of the invention.
Claims (36)
- A process for preparing antibody-drug conjugates (ADC) , wherein the antibody comprises a first and a second antigen-binding moiety,the first antigen-binding moiety comprises: a first heavy chain variable domain (VH) operably linked to a first T cell receptor (TCR) constant region (C1) , and a first light chain variable domain (VL) operably linked to a second TCR constant region (C2) , wherein C1 and C2 are capable of forming one or more non-native interchain disulfide bonds, andthe second antigen-binding moiety comprises a Fab, scFv or VHH,and wherein the process comprises the following steps:(a) incubating a reductant and the antibody in a buffer system;(b) introducing an excess amount of a linker-drug moiety to react with reduced thiol groups resulted from step (a) ; and(c) recovering the resultant antibody-drug conjugates.
- The process according to claim 1, wherein the second antigen-binding moiety comprises a second VH operably linked to an antibody heavy chain CH1 domain and a second VL operably linked to an antibody light chain constant (CL) domain.
- The process according to claim 1 or 2, wherein the incubation in step (a) is performed in the presence of an effective amount of a transition metal ion (s) and/or divalent metal ion (s) .
- The process according to claim 1 or 2, wherein the incubation in step (a) is not performed in the presence of an effective amount of a transition metal ion (s) or divalent metal ion (s) .
- The process according to claim 3, wherein the process further comprises between steps (b) and (c) : removing the metal ions from the product of step (b) , then introducing a reductant again and incubating with an excess amount of a different linker-drug moiety.
- A process for preparing antibody-drug conjugates (ADC) , wherein the antibody comprises a first and a second antigen-binding moiety,the first antigen-binding moiety comprises: a first heavy chain variable domain (VH) operably linked to a first T cell receptor (TCR) constant region (C1) , and a first light chain variable domain (VL) operably linked to a second TCR constant region (C2) , wherein C1 and C2 are capable of forming a non-native interchain disulfide bond (s) , andthe second antigen-binding moiety comprises: a second VH operably linked to an antibody heavy chain CH1 domain, and a second VL operably linked to an antibody light chain constant (CL) domain,and wherein the process comprises the following steps:(a) incubating a reductant and the antibody in the presence of an effective amount of a transition metal ion (s) and/or divalent metal ion (s) in a buffer system to selectively reduce inter-chain disulfide bonds within the antibody;(b) introducing an excess amount of a first linker-drug moiety to react with reduced thiol groups resulted from step (a) ;(c) removing the metal ions from the product of step (b) ;(d) incubating with a reductant (optionally same as the reductant in step (a) ) again and introducing an excess amount of a second linker-drug moiety; and(e) recovering the resultant antibody-drug conjugates.
- The process according to any of the preceding claims, wherein the process further comprises adding an effective amount of oxidant (such as DHAA) to re-oxidize the unreacted thiol groups before recovering the resultant antibody-drug conjugate.
- The process according to any of the preceding claims, wherein the C1 region comprises the amino acid sequence of SEQ ID No: 2, 7 or a variant thereof with at least 90%identity and the C2 region comprises the amino acid sequence of SEQ ID No: 4, 8, 9 or a variant thereof with at least 90%identity, or the C1 region comprises the amino acid sequence of SEQ ID No: 4, 8, 9 or a variant thereof with at least 90%identity and the C2 region comprises the amino acid sequence of SEQ ID No: 2, 7 or a variant thereof with at least 90%identity.
- The process according to any of the preceding claims, wherein the antibody comprises an IgG Fc region, such as in IgG1 or IgG4 isotype, preferably the Fc region comprises a knob into hole structure.
- The process according to any of claims 3-9, wherein the transition metal ions and/or divalent metal ions in step (a) are selected from a group comprising Zn 2+, Cd 2+, Hg 2+, Ca 2+, Mg 2+and any combination thereof.
- The process according to claim 10, wherein the metal ion (s) are selected from Zn 2+, Ca 2+and Mg 2+.
- The process according to any of the preceding claims, wherein the buffer system used in step (a) is selected from a group comprising Hepes, Histidine buffer, PBS, and MES, and the pH value is about 5.5 to 8.
- The process according to any of the preceding claims, wherein the antibody in step (a) is added in a final concentration of about 0.01 to 0.1 mM.
- The process according to any of the preceding claims, wherein step (a) is performed at a temperature of about -10℃ to 37℃, for example, at about 0℃ to 22℃.
- The process according to any of the preceding claims, wherein the reductant in step (a) is TCEP.
- The process according to any of the preceding claims, wherein the linker-drug moiety is maleimide bearing a drug, an organic bromide bearing a drug, or an organic iodide bearing a drug.
- The process according to any of the preceding claims, wherein the drug to be conjugated is selected from a group comprising diagnostic agents, therapeutic agents and labelling agents.
- The process according to any of the preceding claims, wherein the drug is selected from maytansinoids such as DM1, DM3, DM4, dolastatins, dolostatin peptidic analogs and derivatives such as auristatins, calicheamicin, trichothecene, and CC1065, optionally is MMAE, DM1 or MMAF.
- The process according to any of the preceding claims, wherein the process comprises generating the antibody prior to step (a) , wherein the variable regions of the first antigen-binding moiety are derived from a first parental antibody and the variable regions of the second antigen-binding moiety are derived from a second parental antibody.
- The process according to claim 19, wherein the first and second parental antibody is the same.
- The process according to claim 20, wherein the parental antibody is a monospecific, bispecific or multi-specific antibody.
- The process according to any of the preceding claims, wherein the variable regions of the first and second antigen binding moiety are derived from any of the following parental antibodies: trastuzumab, pertuzumab, sacituzumab, abciximab, adalimumab, alefacept, alemtuzumab, basiliximab, belimumab, bezlotoxumab, canakinumab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, golimumab, inflectra, ipilimumab, ixekizumab, natalizumab, nivolumab, olaratumab, omalizumab, palivizumab, panitumumab, pembrolizumab, rituximab, tocilizumab, secukinumab, and ustekinumab.
- The process according to claim 22, wherein the first VH and the first VL are from Trastuzumab and the second VH and the second VL are from pertuzumab, or vice versa.
- The process according to claim 22, wherein the first VH and the first VL are from Trastuzumab and the second VH and the second VL are from sacituzumab, or vice versa.
- The process according to claim 3, wherein the resultant antibody-drug conjugate comprises D2 in a content higher than 80 wt%, for example, higher than 85 wt%, higher than 90 wt%, or higher than 95 wt%, on the basis of total weight of D0 and D2.
- The process according to claim 4, wherein the resultant antibody-drug conjugate comprises D6 in a content higher than 85 wt%, for example, higher than 90 wt%, higher than 91 wt%, higher than 92 wt%, or higher than 93 wt%, on the basis of total weight of D0, D2, D4, and D6.
- The process according to claim 5 or 6, wherein the resultant antibody-drug conjugate comprises D2+4 in a content higher than 65 wt%, for example, higher than 70 wt%, higher than 80 wt%, or higher than 90 wt%, on the basis of total weight of ADCs.
- Antibody-drug conjugates prepared by the process of any one of preceding claims.
- A pharmaceutical composition comprising an effective amount of the antibody-drug conjugates according to claim 28 and a pharmaceutically acceptable carrier or vehicle.
- Use of the antibody-drug conjugates according to claim 28 in the manufacture of a pharmaceutical composition or a kit for treating a condition or disorder in a subject.
- Use of an antibody format in preparing highly homogenous ADCs against selected antigens, wherein the antibody format comprises a first and second antigen-binding moiety,the first antigen-binding moiety specifically binds to a first selected antigen and comprises: a first heavy chain variable domain (VH) operably linked to a first T cell receptor (TCR) constant region (C1) , and a first light chain variable domain (VL) operably linked to a second TCR constant region (C2) , wherein C1 and C2 are capable of forming one or more non-native interchain disulfide bond (s) ,the second antigen-binding moiety specifically binds to a second selected antigen and comprises a second VH operably linked to an antibody heavy chain CH1 domain and a second VL operably linked to an antibody light chain constant (CL) domain, andsaid one or more non-native interchain disulfide bond (s) are not accessible to reductants and cannot be conjugated with a linker-drug moiety.
- The use of claim 31, wherein the highly homogenous ADCs comprise a high content of D6 ADCs, D2 ADCs or bi-drug D2+4 ADCs.
- A method for treating a condition or disorder in a subject, comprising administrating to the subject a therapeutically effective amount of the antibody-drug conjugates according to claim 28 or the pharmaceutical composition according to claim 29.
- The method of claim 33, wherein the condition or disorder is cancer, autoimmune disease, or infectious disease.
- The method of any of claims 33-34, wherein the subject is a mammal, for example, a human.
- A kit, comprising one or more containers comprising the antibody-drug conjugates according to claim 28 or the pharmaceutical composition according to claim 29.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280015068.XA CN117295526A (en) | 2021-09-10 | 2022-09-06 | Method for preparing highly homogeneous antibody-drug conjugates of engineered antibodies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021117709 | 2021-09-10 | ||
CNPCT/CN2021/117709 | 2021-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023036137A1 true WO2023036137A1 (en) | 2023-03-16 |
Family
ID=85506082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/117308 WO2023036137A1 (en) | 2021-09-10 | 2022-09-06 | Process for preparing highly homogenous antibody-drug conjugates for engineered antibodies |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117295526A (en) |
WO (1) | WO2023036137A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024041544A1 (en) * | 2022-08-22 | 2024-02-29 | Suzhou Bioreinno Biotechnology Limited Company | A method of preparing an antibody with site-specific modifications |
WO2024041543A1 (en) * | 2022-08-22 | 2024-02-29 | Suzhou Bioreinno Biotechnology Limited Company | A method of preparing an antibody with thiol group site-specific modifications and use of tcep |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101573384A (en) * | 2006-10-27 | 2009-11-04 | 健泰科生物技术公司 | Antibodies and immunoconjugates and uses therefor |
CN104758946A (en) * | 2015-04-07 | 2015-07-08 | 中国科学院过程工程研究所 | Antibody-coupled drug as well as preparation and application thereof |
CN110317275A (en) * | 2019-05-27 | 2019-10-11 | 浙江大学 | A kind of recombinant antibodies sample T cell antigen receptor, T cell antigen coupled receptors drug, bispecific molecule and application |
CN111484555A (en) * | 2019-01-28 | 2020-08-04 | 正大天晴药业集团股份有限公司 | Novel bispecific CD3/CD20 polypeptide complex |
US20200385440A1 (en) * | 2017-12-07 | 2020-12-10 | Janux Therapeutics, Inc. | Modified bispecific t cell receptors |
WO2021008559A1 (en) * | 2019-07-16 | 2021-01-21 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
WO2021104430A1 (en) * | 2019-11-29 | 2021-06-03 | Wuxi Biologics (Shanghai) Co., Ltd. | A novel anti-cd3/anti-egfr bispecific antibody and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020005676A2 (en) * | 2017-09-22 | 2020-10-20 | WuXi Biologics Ireland Limited | new bispecific polypeptide complexes |
MX2020003144A (en) * | 2017-09-22 | 2020-07-28 | Wuxi Biologics Ireland Ltd | Novel bispecific cd3/cd19 polypeptide complexes. |
KR20210120031A (en) * | 2019-01-28 | 2021-10-06 | 우시 바이올로직스 아일랜드 리미티드 | Novel bispecific CD3/CD20 polypeptide complex |
EP3924378A4 (en) * | 2019-02-15 | 2023-04-05 | WuXi Biologics Ireland Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
-
2022
- 2022-09-06 WO PCT/CN2022/117308 patent/WO2023036137A1/en unknown
- 2022-09-06 CN CN202280015068.XA patent/CN117295526A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101573384A (en) * | 2006-10-27 | 2009-11-04 | 健泰科生物技术公司 | Antibodies and immunoconjugates and uses therefor |
CN104758946A (en) * | 2015-04-07 | 2015-07-08 | 中国科学院过程工程研究所 | Antibody-coupled drug as well as preparation and application thereof |
US20200385440A1 (en) * | 2017-12-07 | 2020-12-10 | Janux Therapeutics, Inc. | Modified bispecific t cell receptors |
CN111484555A (en) * | 2019-01-28 | 2020-08-04 | 正大天晴药业集团股份有限公司 | Novel bispecific CD3/CD20 polypeptide complex |
CN110317275A (en) * | 2019-05-27 | 2019-10-11 | 浙江大学 | A kind of recombinant antibodies sample T cell antigen receptor, T cell antigen coupled receptors drug, bispecific molecule and application |
WO2021008559A1 (en) * | 2019-07-16 | 2021-01-21 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
WO2021104430A1 (en) * | 2019-11-29 | 2021-06-03 | Wuxi Biologics (Shanghai) Co., Ltd. | A novel anti-cd3/anti-egfr bispecific antibody and uses thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024041544A1 (en) * | 2022-08-22 | 2024-02-29 | Suzhou Bioreinno Biotechnology Limited Company | A method of preparing an antibody with site-specific modifications |
WO2024041543A1 (en) * | 2022-08-22 | 2024-02-29 | Suzhou Bioreinno Biotechnology Limited Company | A method of preparing an antibody with thiol group site-specific modifications and use of tcep |
Also Published As
Publication number | Publication date |
---|---|
CN117295526A (en) | 2023-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7021159B2 (en) | Site-Specific Antibodies-Drug Conjugation by Carbohydrate Engineering | |
JP6333882B2 (en) | Antibody-drug conjugate | |
ES2775431T3 (en) | Bispecific Antibodies Binding to CD38 and CD3 | |
WO2023036137A1 (en) | Process for preparing highly homogenous antibody-drug conjugates for engineered antibodies | |
CA2987118A1 (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
US10858435B2 (en) | PD1 binding agents | |
CN110981964A (en) | Novel heterodimeric proteins | |
US11497769B2 (en) | Anti-CD19 antibodies | |
US11834498B2 (en) | Biparatopic FR-alpha antibodies and immunoconjugates | |
WO2021068949A1 (en) | Anti-human trop-2 antibody and application thereof | |
US20230159656A1 (en) | Anti-steap1 antigen-binding protein | |
JP7104153B2 (en) | Combination therapy of anti-progastrin antibody and immunotherapy to treat cancer | |
US20230165967A1 (en) | Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties for use in Treating Cancer, Immunological Disorders, and Methods Thereof | |
CA3196933A1 (en) | Anti-cd3 antibody and uses thereof | |
WO2023092099A1 (en) | Gpc3 binding agents, conjugates thereof and methods of using the same | |
WO2023187130A1 (en) | Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof | |
NZ726501B2 (en) | Human monoclonal antibodies to ganglioside gd2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22866600 Country of ref document: EP Kind code of ref document: A1 |